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SPINAL KAPPA OPIOID RECEPTOR ACTIVITY INHIBITS ADENYLYL 
CYCLASE-1 DEPENDENT MECHANISMS OF CHRONIC POSTOPERATIVE PAIN 
 
Chronic postoperative pain impacts millions of individuals worldwide that undergo 
a variety of surgical procedures. Opioids remain the mainstay analgesics of acute and 
perioperative pain; however, prolonged opioid therapy may lead to life-threating adverse 
effects, tolerance, dependence, and addiction. Therefore, unraveling the cellular 
mechanisms that drive persistent pain states and opposing endogenous analgesia provided 
by opioid receptor signaling, may lead to novel analgesics. Evidence suggests that tissue 
injury leads to increased sensitization of the spinal cord nociceptive neurons which 
increases susceptibility to chronic pain via an N-methyl-D-aspartate (NMDA) receptor 
activation of calcium-sensitive adenylyl cyclase isoform 1 (AC1). This phenomenon, 
named latent pain sensitization (LS), is mediated by a compensatory response of 
endogenous inhibitory systems.  
In this dissertation, we test the hypothesis that surgical insult promotes prolonged 
activation of kappa opioid receptors (KOR) which mask LS via attenuation of pro-
nociceptive AC1 signaling pathways in both male and female animals. We employed a 
murine model of chronic postoperative pain that promotes LS in the spinal cord and closely 
resembles the phenotypic features of postoperative pain in human subjects. When 
behavioral signs of hyperalgesia resolved, we targeted spinal opioid receptor systems and 
pronociceptive modulators with intrathecal delivery of selective pharmacological 
antagonists and assessed behavioral signs of hyperalgesia and spinal nociceptive 
sensitization. We propose that LS is kept in remission by a long-lasting compensatory 
response of tonic endogenous KOR signaling that hinders a pronociceptive LS pathway 
that includes not only AC1 but also two downstream targets: protein kinase A (PKA) and 
exchange protein activated by cAMP (Epac1/2) - in a sex-dependent manner. Our results 
propose new therapeutic targets for the management of persistent postoperative pain and 
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CHAPTER 1. Introduction and Overall Hypothesis 
 
 1.1 Introduction 
Chronic pain is an emergent cause of morbidity and long-term disability worldwide. 
With an estimated minimum 1/3 of the adult United States population suffering from 
chronic pain, the costs in healthcare account for approximately $600 billion annually 
(Medicine, 2011). In fact, 11.2% of Americans report moderate to severe daily pain (Nahin, 
2015), and 4.8% of chronic pain patients exhibit high rates of disability, psychological and 
cognitive impairment (Pitcher et al., 2018).  The increased burden of chronic pain is 
exacerbated by the fact that many patients are refractory to available pharmacological 
interventions. For instance, almost 20% of patients with neuropathic pain are placed on 
long-term opioid regimens as the ultimate resource to manage the pain severity, improve 
their quality of life and functional impairment (Eriksen et al., 2006; Hoffman et al., 2017). 
Among the chronic pain patients on prolonged opioid therapy, over 60% report having 
initiated opioids following surgical procedures (Callinan et al., 2017). Long-term opioid 
therapy, however, it is only moderately effective at best and can lead to not only life-
threatening adverse effects, but also analgesic tolerance, dependence, abuse liability and 
paradoxical pain exacerbation (Eriksen et al., 2006). Therefore, there is an increased need 
for multidisciplinary approaches and research leading to novel and efficacious non-opioid 
treatment modalities for chronic pain.  
One of the significant challenges in pain research is to understand the mechanisms 
of chronic pain and its inhibition. There is a consensus that persistent pain states result 
from maladaptive plasticity of a network of neurons in the CNS, including the dorsal horn 
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of the spinal cord (Sessle, 2000; Latremoliere and Woolf, 2009; Sandkuhler and Gruber-
Schoffnegger, 2012). Tissue injury or inflammation produce increased excitability of 
nociceptive circuits that are driven by N-methyl-D-aspartate (NMDA) glutamatergic 
receptor dependent activities in the central synapses and their downstream pathways 
(Woolf, 2007; Zhuo, 2012). Thus, uncovering the cellular mechanisms that are involved in 
pain-related plasticity is critical for developing more effective pharmacological 
approaches.  
It is well recognized that spinal nociceptive transmission is modulated by activation 
of opioid receptors in the peripheral and central nervous system (CNS) upon coupling of 
exogenous agonists or its endogenous ligands (Yaksh, 1987). We postulate that tissue 
injury is followed by a period of long-lasting pain vulnerability entitled latent sensitization 
(LS), in which sensitized spinal nociceptive pathways remain quiescent due to 
compensatory activity of pain inhibitory systems in the dorsal horn (Solway et al., 2011; 
Corder et al., 2013) that outlasts the resolution of the injury. Disruption of the inhibitory 
systems due to subsequent exposure to an injury (Taylor and Corder, 2014; Pereira et al., 
2015b) or stressful events (Rivat et al., 2007; Marvizon et al., 2015) can trigger episodes 
of hyperalgesia. The silent phase of LS can be unmasked upon administration of the non-
selective antagonist/inverse agonist of opioid receptors-naltrexone or naloxone in rodents 
(Campillo et al., 2011; Corder et al., 2013), and in a subpopulation of susceptible human 
subjects (Pereira et al., 2015b). This phenomenon indicates a compensatory endogenous 
opioid mechanism after injury, where mu opioid receptors (MOR) become constitutively 
active (MORCA) to combat opposing processes of pain transduction, thereby possibly 
preventing the transition from acute to persistent pain states. However, the contribution of 
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other opioid receptor subtypes to LS remains to be determined. Thus, it is conceivable that 
kappa opioid receptors (KOR) may also exert a compensatory long-lasting antinociceptive 
response to repress hyperalgesia after injury. 
MORCA suppresses inflammatory pain in part, via inhibition of AC1 - cAMP 
signaling during LS. Thus, pharmacological blockade of MORCA induces pain 
reinstatement possibly through disinhibition of NMDA-AC1 pathway allowing an increase 
in cAMP and downstream signaling transduction (Corder et al., 2013; Taylor and Corder, 
2014). Recent evidence indicates a role of the c-AMP downstream target protein kinase A 
(PKA) and exchange protein associated with cAMP (Epac) in LS (Fu et al., 2019).  Less 
appreciated; however, is whether males and females differ in LS endogenous control and 
spinal maladaptive plasticity mechanisms. Therefore, we propose that endogenous 
postoperative analgesia would be differentially mediated by tonic KOR-mediated 
inhibition of AC1 and/or downstream c-AMP signaling proteins PKA and Epac in male 
and female mice. 
1.2 Overall Hypothesis and Specific Aims 
 This dissertation tests the overall hypothesis that tissue injury leads to sustained 
activation of kappa opioid receptors (KOR) in the dorsal horn of the spinal cord that 
maintains latent sensitization (LS) within a state of remission, via inhibition of adenylyl 
cyclase-1 (AC1)-dependent pathways in male and female mice.  To test this hypothesis, I 
designed and performed several experiments to examine the following specific aims: 
1. Delineate the contribution of the opioid receptor subtypes to the remission 
phase of LS. 
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2. Determine whether there are sex differences in postoperative endogenous 
opioid receptor analgesia. 
3. Examine whether KOR antagonist-induced reinstatement of hyperalgesia is 
associated with spinal nociceptive neuronal sensitization. 
4. Determine whether KOR postoperative endogenous analgesia (suppression 
of LS) is mediated by inhibition of AC1 and/or downstream PKA and Epac 
mechanisms. 




















CHAPTER 2. General Background 
 
2.1 Overview of Pain: concepts and classification 
Pain is a complex multidimensional experience. Subjective in nature, and 
intrinsically associated with emotional and cognitive factors, it is defined by the 
International Association for the Study of Pain (IASP) as “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage or described in 
terms of such damage” (Merskey H & Bogduk N, 1994).  Thus, the pain experience 
encompasses both a sensory-discriminative and affective-motivational component. The 
first component denotes the perceptual nature of pain; location, intensity, and quality of the 
noxious stimuli can be distinguished via neural processing in the thalamus and 
somatosensory cortices. While, the latter refers to its psychological aspects mediated by 
the limbic system (Basbaum et al., 2009; Braz et al., 2014). Both pain dimensions can be 
assessed experimentally. The sensory component is commonly measured in rodents and 
human laboratory studies using stimulus-evoked tests such as von Frey filaments (Tena et 
al., 2012; Wildgaard et al., 2012), and thermal assays (Woolfe, 1944; Hargreaves et al., 
1988). These assays employ physiological stimuli (i.e., mechanical, thermal, chemical) to 
the limbs (or face) to assess changes in pain thresholds determined by the withdrawal or 
escape latency from innocuous or noxious stimuli (Deuis et al., 2017). Similarly, the 
affective-motivational dimension of pain is characterized by a negatively reinforcing 
component that can be defined in preclinical studies using motivation to seek pain relief 
assays in rodents such as Conditioned Place Preference or Conditioning Place Avoidance 
paradigms (He et al., 2012; Griggs et al., 2015).  While, it is assessed in the clinical setting 
by self-report pain scales or self-administered questionnaires (Hardt et al., 2000; Martin et 
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al., 2019). This dissertation will focus primarily on stimulus-evoked tests (von Frey-
filament) to assess mechanical hypersensitivity following surgery and pharmacological 
manipulations of the opioid receptor systems.  
As previously highlighted, pain is highly subjective and relies on patients’ self-
report. Thus, the term nociception, defined as neural processes of noxious stimuli detection 
and processing (Basbaum et al., 2009)  better applies to preclinical research, thereby it will 
be used throughout this work. Acute (nociceptive) pain is fundamental for survival, as it 
serves as a protective apparatus to inform the organism about imminent threats to avoid 
further tissue damage and allow healing. Nociceptive stimuli are encoded by specialized 
subpopulations of peripheral neurons, so-called nociceptors that transmit the noxious 
signals to the first relay center of information in the CNS, the dorsal horn of the spinal cord 
(or subnucleus caudalis in the brainstem for facial and cephalic stimuli). There the noxious 
signals are processed and modulated before ascending to the higher centers in the brain 
where the pain is perceived.  The importance of acute pain is underlined in individuals with 
congenital insensitivity to pain, in which the inability of detecting noxious stimuli due to 
non-functional nociceptors leads to repeated severe injuries and reduced life expectancy 
(Cox et al., 2006; Goldberg et al., 2007). 
Pain is often categorized based on its duration. Acute pain is short-lived, lasting 
from minutes to several weeks, and has a distinct etiology, such as tissue damage, 
inflammatory processes or surgical intervention. If undertreated, acute pain may progress 
to persistent pain states, lacking its biological function and becoming a disorder itself. 
Chronic pain is multifaceted, accompanied by physical and psychiatric comorbidities, and 
is, therefore, one of the most critical challenges in the clinic setting. It can exacerbate over 
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time and persist from 4 months (IASP) to years, or even a lifetime. It may arise from 
unremitted injuries (low back pain, postoperative pain), or be associated with a disease 
(i.e., rheumatoid arthritis, diabetes). However, many of these clinical entities lack a clear 
etiologic factor, such as fibromyalgia and chronic daily migraines. In an attempt to solve 
this gap in the pain classification, the IASP recently adopted the terminology of nociplastic 
pain to embrace the conditions that arise from altered nociception but are devoid of a 
recognizable causal factor or associated disease (IASP, 2017).  Moreover, chronic pain 
patients can suffer from constant pain or experience episodes of remission as in low back 
pain or persistent postoperative pain. In this dissertation, we adopted a preclinical model 
of persistent postoperative pain due to its high prevalence and incidence, and identifiable 
etiology that allows the investigation of putative mechanisms involved in the transition 
from acute to chronic pain.  
2.2 Postoperative pain: epidemiology and therapeutics 
It is estimated that approximately 40% of chronic pain patients report that their 
symptoms were initiated after trauma or surgical intervention (Schug SA & Pogatzki-Zahn 
EM, 2011). Over 300 million surgeries are performed annually worldwide (Weiser et al., 
2016) and up to 80% of patients may experience postsurgical pain (Apfelbaum et al., 2003). 
Among them, women report higher postoperative pain levels than men (Storesund et al., 
2016), and recent evidence indicates that females are at higher risk to develop persistent 
pain after surgery (Schug AS & Pogatzki-Zhan EM, 2011). Persistent postoperative pain 
is a significant burden to society as it impairs the quality of life of 5% to 85% of patients 
that undergo a variety of surgical procedures every year (Schug AS & Pogatzki-Zhan EM, 
2011).  It is defined as constant or intermittent pain in the surgical site (primary 
8 
hyperalgesia) or surrounding area (secondary hyperalgesia) that persists for at least three 
months after the surgical procedure (Macrae, 2008; Werner and Kongsgaard, 2014). The 
pain exhibits both inflammatory and neuropathic features as transoperative nerve damage 
may occur (Kehlet et al., 2006; Haroutiunian et al., 2013). 
The increased rate of chronic postoperative pain reflects, at least in part, the 
inadequacy of currently available treatments. It is also possibly due to a disconnect between 
the findings of fundamental research and clinical practice (Gerbershagen et al., 2014; 
Cooper et al., 2016). To date, opioids remain the first line of treatment for acute 
postoperative pain; however, its adverse effects including nausea, vomiting, and 
constipation, the risk of respiratory depression, dependence, and addictive properties 
compromise its effectiveness (Al-Hasani and Bruchas, 2011). Moreover, opioids are less 
efficacious in cases with a strong neuropathic component, and when used preoperatively 
increase the likelihood of persistent pain after surgery (VanDenKerkhof et al., 2012). 
Current guidelines advise multimodal protocols encompassing cyclooxygenase inhibitors-
2 (COX-2) and NMDA antagonists. When neuropathy is present, drugs that reduce 
neurotransmission and membrane stabilizers are recommended perioperatively (Chou, 
2016). A recent meta-analysis supports the use of the α2δ ligands, gabapentin and 
pregabalin, perioperatively to reduce the risk of persistent surgical pain (Clarke et al., 
2012). Despite the multitude of available therapies to treat acute postoperative pain, there 
is no highly effective prophylactic drug to manage chronic postsurgical pain. Therefore, 
drugs with potent analgesic properties and low addictive effects are warranted. 
Here, we adopted a preclinical model of postoperative pain where a 5mm incision 
is performed on the mouse hindpaw through the glabrous skin, fascia and plantaris muscle 
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under general anesthesia, precipitating non-evoked guarding behavior of the limb that lasts 
1 to 2 days and mechanical hypersensitivity that persists up to 3 weeks (Pogatzki and Raja, 
2003). The intraoperative procedure of skin and fascia incision, muscle retraction and 
behavioral presentation closely recapitulate the postoperative pain phenotype in patients 
(Pogatzki-Zahn et al., 2007; Pogatzki-Zahn et al., 2017). After hyperalgesia subsides, 
pharmacological approaches are used to target the opioid receptor system and key pain 
modulators of spinal neuroplasticity, which in turn leads to reinstatement of pain behavior 
and replicates persistent postsurgical states in patients. This model allows us to investigate 
potential novel therapeutic targets involved in chronic pain consolidation such as AC1 and 
downstream proteins Epac1/2. 
2.3 Anatomy of nociceptive circuitry in the dorsal horn of the spinal cord 
In the periphery, free nerve terminals from primary afferent neurons transduce 
noxious stimuli into electrical signals (action potentials) that are conveyed to the CNS. The 
dorsal horn of the spinal cord is the primary point of conversion of nociceptive inputs from 
the periphery to high centers in the brain. The dorsal horn receives information from 
heterogeneous groups of neurons responsible for processing and intense modulation of 
noxious inputs before these signals ascend to the brain, where pain perception occurs. The 
dorsal horn neurons are comprised of four groups: (1) central terminals of primary 
afferents; (2) interneurons; (3) projection neurons; (4) descending axons from the 
brainstem (Todd A and Koeber H, 2015).  This work focuses on the first three populations 




The dorsal horn neurons are organized within a distinct laminar pattern (I-VI) 
according to their functional class (Rexed, 1952). The superficial dorsal horn is the primary 
region of relay for the primary afferent neurons and is comprised of laminae I or marginal 
layer, and lamina II or substantia gelatinosa. Interneurons predominate in laminae I-III, 
while the deeper laminae IV-VI are sites of synapse of primary sensory and projection 
neurons (Figure 2.1.A) (Basbaum et al., 2009; Braz et al., 2014; Todd, 2017).  
2.3.1 Primary sensory afferent inputs into the dorsal horn 
Nociceptive primary afferents are specialized peripheral sensory neurons that 
encode intense, noxious (i.e., mechanical, thermal, chemical) stimuli from the periphery 
into the dorsal horn. Nociceptors are pseudo-unipolar neurons; the body of the neuron 
arising from the limbs and trunk lies on the dorsal root ganglia (DRG). Their axons diverge 
from the DRG to give rise to peripheral branches that innervate the skin, viscera, 
musculoskeletal system, and blood vessels; and central terminals that synapse with second-
order neurons in the dorsal horn.  
The primary afferent neurons are somatotopically organized in humans and 
animals. In mice, the innervation of the hindpaw and lower limbs is supplied by three 
subdivisions of the sciatic nerve: tibial, common peroneal and sural nerves that emerge 
from the lumbar spinal nerves L3-L5. The sciatic nerve in mice is composed predominantly 
of fibers originating at the L3 and L4 DRGs. Retrograde labeling and behavioral studies 
demonstrated that in the C57Bl/6 mouse strain, the primary anatomical and somatosensory 
contribution is predominantly provided by L4 (Rigaud et al., 2008). Therefore, in our 
immunofluorescent assay, we evaluated the cellular markers at the L4 segment of the dorsal 




Figure 2.1. Dorsal horn pain transmission pathways.  
(A) Close sagittal view of the dorsal horn of the spinal cord. The distinct populations of 
primary afferent fibers synapse with projection neurons in laminae I (red) and V (purple), 
and interneurons from laminae II outer (green) to IV (black). (B) Ascending tracts from the 












Based on their physical properties, the nociceptors are classified into two main 
groups: A-delta (Aδ), and C-fibers. Aδ fibers are medium in diameter and thinly 
myelinated, with conduction velocity >2m/s. They project to lamina I and V where they 
synapse with projection neurons. They are highly discriminative and are thought to mediate 
fast, sharp, aching, well-localized pain. Conversely, C-fibers are small in diameter, 
unmyelinated, and therefore have slower conduction velocity (< 2m/s).  The C-fibers are 
subdivided into peptidergic and non-peptidergic subsets, expressing substance P (SP), 
calcitonin gene-related peptide (CGRP), and transient vanilloid receptor, isoform 1 
(TRPV1) receptors; and isolectin IB4 respectively. The peptidergic C-fibers project to 
lamina I and lamina II outer; whereas non-peptidergic fibers project to lamina II inner and 
synapse with interneurons, creating complex circuits within the dorsal horn.  C-fibers 
possibly mediate more diffuse and slow pain. Both, C- and Aδ fibers are polymodal, 
responding to tactile, thermal and chemical stimuli.  
The third subtype of peripheral sensory afferents is the large diameter and fast 
conduction A-beta (Aβ) fibers. They project to lamina III-V and are responsive for low 
threshold mechanical stimuli in physiological conditions (Figure 2.1.A). In the injury 
setting, they become responsive to noxious stimuli, leading to increased hypersensitivity 
to innocuous tactile stimulation, named allodynia (Basbaum et al., 2009; Todd, 2010; Braz 
et al., 2014). 
2.3.2 Dorsal horn interneurons 
The nociceptive inputs delivered by the primary sensory neurons in the dorsal horn 
are the subject of intense modulation by interneurons.  Interneurons outweigh the other 
neuronal cells throughout the dorsal horn. For example, the superficial lamina is composed 
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of a small fraction (> 5%) of projections neurons (Campbell et al., 1998), and at least 90-
95% of interneurons (Spike et al., 2003; Abraira and Ginty, 2013). While lamina II and III 
are composed almost, if not exclusively, of interneurons. Functionally, interneurons can be 
divided into excitatory and inhibitory cells (Todd, 2010). Excitatory interneurons 
synthesize glutamate as their main neurotransmitter and can be detected by vesicular 
glutamate transporter 2 (VGLUT2) immunoreactivity in their axons (Todd et al., 2003). 
Inhibitory interneurons synthesize γ- aminobutyric acid (GABA) or glycine as their main 
neurotransmitters and can be identified by vesicular GABA transporter (VGAT), and 
glutamate decarboxylase (GAD67) (Mackie et al., 2003; Todd, 2010). Recently, the dorsal 
horn excitatory and inhibitory interneurons have been also categorized 
immunohistochemically by the expression pattern of the homeobox genes T-C-Leukemia 
homeobox 3 (Tlx3) (Cheng et al., 2004; Xu et al., 2008b), and paired box gene2 (Pax2) 
(Batista and Lewis, 2008) respectively. 
Subpopulations of dorsal horn interneurons have also been identified based on their 
electrophysiological properties and neurochemical markers. The identification of these 
distinct populations of interneurons has been instrumental in uncovering the dorsal horn 
circuits and their contribution to pathological pain (Miraucourt et al., 2007; Duan et al., 
2014; Petitjean et al., 2015; Peirs and Seal, 2016). Of particular interest for this dissertation 
are the populations of opioid-expressing interneurons. MOR interneurons are expressed in 
excitatory interneurons (Kemp et al., 1996) in  lamina IIi and IIo  (Corder et al., 2017; Wang 
et al., 2018) and are thought to be part of a polysynaptic circuit involved in the inhibition 
of ascending inputs via projection neurons in lamina I and V (Eckert et al., 2003; Chen et 
al., 2005).  Similarly, DOR-containing interneurons are mostly excitatory and located at 
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the ventral aspect of lamina IIi. However, emerging evidence indicates that DOR and MOR 
are co-expressed in a few subsets of interneurons, and they internalize and function 
independently (Wang et al., 2018).  
The expression of KOR in spinal circuits still debatable, IHC studies suggest that 
they are expressed in inhibitory interneurons. Dynorphin, the KOR endogenous ligand, is 
present in both excitatory and a subset of inhibitory interneurons of the superficial dorsal 
horn (Todd, 2010; Boyle et al., 2017). In the setting of inflammatory pain, inhibitory-
expressing dynorphin interneurons play a central role in the mechanical gate circuitry 
precluding the development of mechanical allodynia (Duan et al., 2014). However, spinal 
dynorphin peptide exerts not only anti-nociceptive, but also pro-nociceptive actions 
(Podvin et al., 2016). For example, in preclinical models of neuropathic pain and chronic 
inflammation, upregulated spinal dynorphin promotes hyperalgesia possibly via an opioid-
independent mechanism (Tan-No et al., 2004; Lai et al., 2006; Luo et al., 2008). 
2.3.3 Ascending pathways from dorsal horn to the brain 
Nociceptive signals from the dorsal horn are transmitted to the brain via projection 
neurons located within lamina I and the deep dorsal horn. The projection neurons are 
mostly concentrated in lamina I and are nociceptive specific. Conversely, the deep dorsal 
horn contains nociceptive specific and wide-dynamic range neurons (WDR) that are 
sensitive to both innocuous and noxious stimuli (Braz et al., 2014).   Immunohistochemical 
studies identified that the vast majority of lamina I and some deep dorsal horn projection 
neurons are neurokinin 1 receptor (NK1) positive cells that are activated upon release of 




From lamina I and V projection neurons, noxious inputs travel to the contralateral 
side and ascend to higher brain centers via the spinothalamic and spinoreticulothalamic 
tracts (Figure 2.1.B). The NK1 positive cells form synapses with neurons within the lateral 
parabrachial nucleus (PBN), rostral ventral medulla (RVM), and periaqueductal gray 
(PAG) and send projections to six distinct nuclei in the thalamus (Todd et al., 2002; Craig, 
2003). From the thalamus, third order neurons convey to the primary (S1) and secondary 
(S2) somatosensory cortices, where conscious perception is established, and the 
discriminative aspects of pain are recognized.  Alternatively, the PBN sends connections 
to limbic structures promoting modulation of the affective and contextual facets of pain 
(Ossipov et al., 2014).   
2.4 Nociceptive plasticity in the dorsal horn  
 As previously highlighted, the dorsal horn is a primary integrative center for 
transduction and processing of nociceptive information.  Thus, the spinal nociceptive 
circuits are under the constant influence of afferent inputs and modulation from descending 
controls to adapt to potential damage. It is generally recognized that tissue injury leads to 
peripheral sensitization and increased responsiveness of dorsal horn nociceptive neurons 
to normal and sub-threshold afferent inputs, a process termed central sensitization (IASP), 
that is implicated in the development of persistent pain states (Latremoliere and Woolf, 
2009; Sandkuhler and Gruber-Schoffnegger, 2012).   
Central sensitization relies on NMDA receptor (NMDAR) activity. For instance, 
perioperative non-selective NMDA antagonist administration reduces postoperative pain 
in rodents (Pogatzki et al., 2000; Shen et al., 2016) and patients (Stubhaug et al., 1997). At 
the cellular level, NMDAR activation leads to increased cytosolic calcium (Ca2+) and 
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subsequent activation of several downstream substrates such as Ca2+/calmodulin-sensitive 
adenylyl cyclases  (Zhuo, 2012), and the kinases PKA, PKC and extracellular signal-
regulated kinase (ERK1/2). These kinases modulate the activity of glutamate ionotropic 
receptors and trigger transcriptional events (Kawasaki et al., 2004; Latremoliere and 
Woolf, 2009). The consequent increased excitability and efficacy of dorsal horn synapses 
following injury results in a central amplification response and enlargement of receptive 
fields which leads to pain from normally innocuous stimuli (allodynia) and heightened pain 
sensitivity to noxious stimuli (hyperalgesia) at neighboring non-injury sites (secondary 
hyperalgesia) that are commonly observed in chronic pain conditions (Woolf, 2007, 2011).    
In this work, we used a series of manual von Frey filaments with incremental force 
increases to evaluate punctate hyperalgesia or allodynia (Chaplan et al., 1994). As the 
distinction between allodynia and hyperalgesia in rodent models of pain is challenging, the 
term hypersensitivity is commonly applied throughout this dissertation. In addition, we 
evaluated nociceptive plasticity in the dorsal horn using immunofluorescence of 
phosphorylated ERK (pERK), as a marker of central sensitization.   
2.5 Latent central sensitization as a model to investigate the transition from acute to 
chronic pain states  
 The central sensitization of dorsal horn nociceptive neurons induced by tissue 
trauma can persist beyond healing and recovery from behavioral signs of hyperalgesia. 
This persistent spinal sensitization is outweighed by tonic activity of the inhibitory systems 
in a silent form of neuroplasticity named latent sensitization (LS) (Figure 2.2) (Solway et 
al., 2011; Taylor and Corder, 2014; Walwyn et al., 2016).  Previous studies indicate that 
sensitization of spinal neurons arising from surgical incision facilitates the recruitment of 
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opioid receptors (Nagakura et al., 2008). Likewise, compelling data from our laboratory 
indicate that LS is maintained in a remission phase by mu opioid receptor constitutive 
activity (MORCA). For example, administration of MOR inverse agonists elicited 
behavioral signs of withdrawal and hyperalgesia when given 21 days after hindpaw 
injection of Complete Freund’s Adjuvant (CFA) or paw incision, but not in sham animals. 
Moreover, this injury-induced spinal sensitization lasts at least several months under the 
inhibitory control of mu opioid receptor systems (Corder et al., 2013).  
Interestingly, LS can be transiently unmasked by Gi/o-protein receptor antagonists 
(Campillo et al., 2011; Solway et al., 2011; Walwyn et al., 2016), chronic administration 
of opioid agonists (Celerier et al., 2001; Li et al., 2001; Lian et al., 2010) and stress (Rivat 
et al., 2007; Le Roy et al., 2011; Romero et al., 2017; Chen et al., 2018a). Therefore, LS 
models resemble episodic chronic pain conditions triggered by, i.e., stressors or subsequent 
injury and that are characterized by periods of remission. Thus, it may represent a critical 
stage of pain vulnerability. In summary, these studies suggest that sustained signaling of 
endogenous opioid receptor systems exert a crucial role in the modulation of pain after 
injury, and any impairment in these protective systems may result in persistent pain states. 
Therefore, LS is a robust, highly repeatable phenomenon, well characterized in rodents 
(Taylor and Corder, 2014; Marvizon et al., 2015) and observed in a subset of human 
subjects (Pereira et al., 2015b; Pereira et al., 2015a). As such, it is a suitable model to 
investigate the poorly understood cellular and molecular mechanisms involved in the 
transition from acute to pathological pain states.    
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Figure 2.2 Schematic summarizing the sequence of events that occur after injury, 
leading to a dynamic relationship between the systems that regulate analgesia and 
pain.  
Severe tissue injury triggers the development of latent nociceptive sensitization (LS, green 
line). A compensatory kappa-opioid receptor-mediated (KOR, blue line) analgesia 
silences LS, contributing to pain resolution (pain, red line). If the balance is disturbed, i.e., 
blockade of tonic KOR activity (dotted line), LS manifests as spinal neuronal sensitization 
and pain reinstatement. [Adapted from Taylor & Corder, 2014]. 
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To help answer some of these questions, we employed a translational model of 
chronic postoperative pain in mice, where a paw incision is performed, and numerous 
behavioral signs of hyperalgesia are observed for 2-3 weeks (Pogatzki and Raja, 2003). 
After the recovery of mechanical thresholds, the spinal nociceptive system is challenged 
with either selective opioid antagonists and/or drugs targeting key pain modulatory 
proteins, leading to the reinstatement of hyperalgesia (Figure 2.2).  In chapter 3, we 
investigate the spinal opioid receptor systems that counterbalance the sustained 
pronociceptive inputs in the dorsal horn following surgical incision of the hindpaw.  In 
chapter 4, we designed experiments to uncover cellular signaling pathways underlying LS 
after surgery and to investigate mechanisms by which spinal kappa opioid receptor activity 
suppresses postoperative pain.   
A major gap in the literature is that most animal studies on postoperative pain 
focused on males. Although, women report high levels of postoperative pain (Storesund et 
al., 2016), respond to opioid drugs differently than man (Gear et al., 1996a; Gear et al., 
1996b), and are at higher risk to develop persistent pain (Kehlet et al., 2006). Therefore, 
we included female animal cohorts to assess putative sex differences in both arms: 
endogenous opioid receptor analgesia and the persistent neuroplastic changes (LS) 
associated with the induction and maintenance of chronic pain after surgery. 
2.6. Mediators of spinal nociceptive transmission  
 
 2.6.1 Adenylyl cyclase, isoform 1 (AC1) 
 
           Adenylyl cyclase type I (AC1) is a membrane-bound calcium/calmodulin-sensitive 
enzyme that catalyzes the synthesis of cyclic adenylyl monophosphate (cAMP) in 
mammals. AC1 has been implicated in the modulation of synaptic plasticity and pain (Wu 
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et al., 1995; Liauw et al., 2005; Wei et al., 2006; Zhuo, 2012; Corder et al., 2013), and it is 
primarily expressed in the post-synaptic membrane of central and adrenal neurons and 
retinal cells (Xia et al., 1993; Xia and Storm, 1997; Conti et al., 2007; Wang et al., 2011). 
AC1 links NMDA activity-dependent increases of intracellular calcium and downstream 
cAMP signaling pathways, functioning as a key protein for the induction of pain-related 
plasticity in the CNS. Consequently, AC1 pharmacological or genetic manipulation does 
not alter nociception but may impact the development of persistent pain states (Vadakkan 
et al., 2006; Zhuo, 2012). For example, animals receiving systemic administration of the 
selective AC1 inhibitor, NB001, and AC1KO mice show reduced mechanical hyperalgesia 
after peripheral inflammation or nerve injury (Wei et al., 2002; Wang et al., 2011; Corder 
et al., 2013; Griggs et al., 2017). Moreover, AC1 mutant mice exhibit reduced spinal LTP 
induced by co-administration of serotonin and cAMP-induced by forskolin in the spinal 
cord slices of adult mice (Wang and Zhuo, 2002), and reduced activation of ERK signaling 
following peripheral inflammation (Wei et al., 2006). Similarly, AC1 is required for the 
development of hyperalgesia in the late stages of a preclinical model of chronic 
musculoskeletal pain (Vadakkan et al., 2006).  
          Conversely, AC1 is tonically inhibited by opioids and other Gi/o–coupled receptors.  
Cumulative evidence from our laboratory indicates that AC1 is necessary for the 
maintenance of LS (Corder et al., 2013). In summary, activation of AC1 leads to increased 
intracellular cAMP levels that target downstream effector proteins engendering sustained 
nociception.  In Chapter 3, we investigate the hypothesis that KOR signaling opposes LS 
following surgical incision via prolonged inhibition of AC1 and one or both cAMP target 
proteins: protein kinase A (PKA) and exchange protein activated by cAMP (Epac). We 
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also explore potential sex differences in these c-AMP-mediated pronociceptive pathways 
of LS. 
2.6.2 Protein Kinase A (PKA) 
Protein phosphorylation is a crucial mechanism for the regulation of nociceptive 
signal transduction and transmission in the pain pathways. Protein kinase A (PKA) is a 
classic cAMP-dependent kinase (Walsh et al., 1968) that has been implicated in the 
regulation of nociception and pain-related synaptic plasticity in the spinal dorsal horn 
(Sandkuhler, 2007; Latremoliere and Woolf, 2009). PKA is a heterotetrameric complex 
composed of two regulatory and two catalytic subunits.  It is activated upon binding of 
cAMP to its regulatory domains that lead to dissociation of the catalytic subunits, which in 
turn activate a myriad of intracellular substrates (Cheng et al., 2008). 
Recent evidence from our laboratory indicates that PKA contributes to LS after 
peripheral inflammation and nerve injury (Fu et al., 2019).  PKA contributes to the 
enhancement of spinal synaptic plasticity via phosphorylation of glutamate ionotropic 
receptors following peripheral inflammation or robust noxious stimuli. For example, 
phosphorylation of (alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid) AMPA 
receptors GluR1 subunits leads to increased receptor trafficking and membrane insertion 
(Fang et al., 2003; Latremoliere and Woolf, 2009). Similarly, PKA-related phosphorylation 
of the NR1 subunit of NMDAR (Zhou et al., 2000) enhances receptor function and leads 
to the development of hyperalgesia (Caudle et al., 2005; Gao et al., 2005). Taken together, 
these findings indicate that activation of PKA after injury potentiates the expression and 
function of the postsynaptic ionotropic glutamatergic receptors, neurotransmitter release 
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and spinal synaptic transmission, and possibly contributing to enhancing persistent pain 
states (Aley and Levine, 1999; Araldi et al., 2015, 2016).  
2.6.3 Exchange protein directly activated by cAMP (Epac)  
AC1 - cAMP signaling can also modulate nociceptive plasticity via PKA-
independent pathways. Epacs (Epac, isoform 1 and Epac, isoform 2) are highly conserved 
cAMP sensor proteins that act as guanine nucleotide exchange factors for small GTPases 
(de Rooij et al., 1998; Bos, 2003, 2006).  Epac 1 is ubiquitously expressed, while Epac 2 
is primarily neuronal (Kawasaki et al., 1998). Epacs are activated as cAMP binds to the 
regulatory motif (CNB) leading to its dissociation from the catalytic region and subsequent 
activation of Rap GTPases (Chen et al., 2013).  In vitro and in vivo studies indicate that 
Epacs mediate mechanical hyperalgesia (Wang et al., 2013; Singhmar et al., 2016); 
following nerve injury (Singhmar et al., 2018) and persistent inflammation through 
activation of protein kinase C (PKC) in small, non-peptidergic fibers (Griffin, 2005; Hucho 
et al., 2005). Furthermore, peripheral inflammation enhances the expression of Epacs and 
subsequent up-regulation of multiple PKC isoforms in the DRG (Gu et al., 2016).  
Similarly, recent evidence suggests that Epac 1 and Epac 2 are activated during LS induced 
by surgical incision (Matsuda et al., 2017). Altogether, these results indicate that Epacs are 
key modulators in the development of persistent pain states, and therefore may represent a 
promising therapeutic target for pain management. 
2.6.4 Phosphorylated Extracellular Signal-Regulated Kinase (pERK)  
Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated 
protein kinase (MAPKs) family which is important for intracellular signaling transduction. 
The ERK isoforms 1 (ERK1) and 2 (ERK2) are expressed in the spinal cord and are 
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activated in the dorsal horn following tissue injury or inflammation. ERK phosphorylation 
is found most abundantly in lamina I and II, where most nociceptor afferents relay and 
NK1 neuronal body are located, and are scattered in lamina III to V of the spinal cord (Ji 
et al., 1999; Zhuang et al., 2005; Ji et al., 2009).  
Tissue injury promotes the activation of multiple neurotransmitter systems and 
kinases that leads to ERK phosphorylation and contributes to neural plasticity and 
nociceptive sensitization. For example, peripheral inflammation leads to the release of SP 
and glutamate, which in turn actives neurokinin 1 receptor (NK1R) or AMPAR and 
NMDAR. The subsequent rise of intracellular Ca+2 elicits the activation of AC1 and several 
cAMP effectors including PKA and PKC. All these substrates are reported to contribute to 
ERK1/2 activation in vivo and in ex vivo spinal cord slices (Ji et al., 1999; Kawasaki et al., 
2004; Wei et al., 2006; Chen et al., 2018c). Once activated, pERK perpetuates the 
phosphorylation and trafficking of glutamatergic receptors (Kohno et al., 2008; Ji et al., 
2009), and contributes to CREB phosphorylation and transcription of genes such as c-Fos 
and prodynorphin (Kawasaki et al., 2004). Thus, pERK contributes to both induction and 
maintenance of central sensitization, and possibly the pronociceptive component of latent 
sensitization (Chen et al., 2018c). 
 In naïve animals or baseline conditions, intense noxious stimuli are necessary to 
activate ERK, while low threshold or mechanical stimuli (i.e., light touch) are sufficient 
for ERK activation after injury (Wang et al., 2004; Gao and Ji, 2010). Moreover, pERK 
expression is increased after Therefore, in chapter 3 and 4 we will evaluate pERK 
immunoreactivity in the dorsal horn, as a marker of central sensitization, which is 
detectable 5-10 minutes after nociceptive insult (i.e., pharmacological blockade of opioid 
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receptors) (Gao and Ji, 2009) followed by innocuous (i.e., light touch) stimuli (Ji et al., 
2009; Corder et al., 2013) in post-incisional and sham animals.  
2.7 Endogenous opioid receptor systems and pain 
The opioid receptor system consists of four highly conserved seven-transmembrane 
G-protein coupled receptors (GPCRs), the classic mu (MOR), delta (DOR), kappa (KOR),
and the closely-related family nociceptin opioid peptide (NOP) receptors. These receptors 
are ubiquitously expressed in the peripheral tissues and central neurons (Al-Hasani and 
Bruchas, 2011) (Figure 2.3), neuroendocrine and immune cells. All four receptor subtypes 
were characterized molecularly and pharmacologically (Table 2.1). Upon binding of 
endogenous ligands (beta-endorphin, enkephalin, dynorphin, and nociception/orphanin 
FQ) and/or exogenous agonists they exert potent antinociceptive effects (Yaksh, 1987; 
Mansour et al., 1988; Yaksh et al., 1988). The ligands bind to open pockets composed by 
the extracellular and transmembrane domains. All four receptor subtypes structures were 
initially characterized in an inactive form upon binding of selective antagonists. 
Remarkably, MOR and KOR were recently identified under their active state (Manglik et 
al., 2016; Che et al., 2018). This configuration facilitates the development of new 
compounds and has been the subject of excitement in the field of opioid pharmacology 
(Manglik et al., 2012; Manglik et al., 2016).  
Opioid receptor activation at different nervous system loci modulates spinal 
nociceptive transmission via stimulation of G protein-dependent and independent signaling 
pathways. All four receptor subtypes are coupled to a heterotrimeric inhibitory Gαi/o─Gβγ
protein complex. Ligand binding or increased constitutive activity (Corder et al., 2013; 
Polter et al., 2017) alters the opioid receptor configuration, where Gαi/o and Gαβγ subunits 
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dissociate, leading to the inhibition of adenylyl cyclase - cyclic adenosine monophosphate 
(cAMP) - dependent signaling pathways (Childers, 1991; Childers et al., 1992; Reisine and 
Bell, 1993). As a result, the opening of voltage-gated Ca2+ channels (VGCC) is reduced 
(Dickenson et al., 1987; Sullivan et al., 1989; Kohno et al., 1999; Kondo et al., 2005), 
decreasing neuronal excitability and neurotransmitter release. Additionally, at the post-
synaptic membrane Gαβγ complex increases G protein-coupled inwardly rectifying 
potassium channel (GIRK) conductance, which further hyperpolarizes the neuron 
(Logothetis et al., 1987). Collectively, opioid receptor agonists decrease neuronal 
transmission and promote robust antinociception (For comprehensive review please see 
(Al-Hasani and Bruchas, 2011; Corder et al., 2018).  
This dissertation will focus primarily on the pharmacological effects of antagonists 
of the classic opioid subtypes (MOR, DOR, and KOR, Table 2.2) in unmasking 





Figure 2.3. Loci of analgesic actions of opioids in pain pathways. 
Opioid receptors are expressed throughout the nociceptive pathways. Endogenous and 
exogenous opioids exert their analgesic actions in the peripheral tissues (1), pre- and post-
synaptically in the spinal cord (2), and brain (3) (black arrows, pain transmission = 
ascending pathways); and in descending modulatory tracts from the brainstem - midbrain 
periaqueductal grey (PAG) and rostral ventromedial medulla (RVM) (red arrows, pain 
modulation = descending pathways). (Adapted from Al Hasani & Bruchas, 2011). 
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Table 2.1 Opioid receptor systems gene and pharmacological characterization.   
The classic opioid subtypes’ and respective genes with endogenous and exogenous ligands.  
[Adapted from (Puig and Montes, 1998; Dickenson and Kieffer, 2013)].    
* Drugs used in this dissertation. 
L= long-acting; N= natural product.  
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2.7.1 Delta opioid receptors  
 Delta opioid receptors (DOR) were the first opioid receptor subtype cloned (Evans 
et al., 1992; Kieffer et al., 1992). Similarly to MORs and KORs, they are highly conserved 
across species (Knapp et al., 1995). DORs regulates both nociception and opioid tolerance. 
Their analgesic effects at the spinal cord level were confirmed in studies using DOR KO 
mice (Zhu et al., 1999) and pharmacological manipulations. A distinct feature of DOR is 
that it is found mostly in intracellular structures (Cahill et al., 2001) of sensory neurons and 
traffic to the cell surface in response to agonist administration (Gendron et al., 2006), 
chronic inflammation or opioid administration (Cahill et al., 2003). In contrast, recent 
studies using DOR-GFP mice revealed a relatively high expression of DORs at the 
neuronal membrane under physiological conditions (Scherrer et al., 2009; Wang et al., 
2018).  
 Several lines of evidence suggest that DORs exert their analgesic actions, at least 
in part, due to heterodimerization with MORs (Gomes et al., 2000; Kieffer and Gaveriaux-
Ruff, 2002; Gendron et al., 2006). Although, recent studies using DOR-GFP indicate that 
despite significant (~50%) co-localization with MORs in projection neurons in lamina I, 
they are expressed mostly in distinct populations of interneurons and function 
independently (Wang et al., 2018).  In addition, DORs are present in the non-peptidergic 
and mechanosensory myelinated nociceptors that project to the skin and are involved in 
mechanical hypersensitivity in chronic pain states (Scherrer et al., 2009; Bardoni et al., 
2014). Thus, DOR activation is involved in the control of mechanical pain. Moreover, 
microinjection of DOR agonists in the rostral ventral medulla (RVM) leads to 
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antinociceptive effects in chronic inflammatory models of pain, indicating a supraspinal 
descending inhibitory control of DORs (Hurley and Hammond, 2000). 
2.7.2 Mu opioid receptors 
MOR is the main target of most opiate drugs available to treat severe pain.  It 
promotes robust antinociceptive effects once activated by its endogenous peptides β-
endorphin or exogenous ligands such as morphine. However, prolonged use of opioid 
agonists are associated with multiple severe adverse effects including tolerance, 
dependence, respiratory depression and opioid induced hyperalgesia (Al-Hasani and 
Bruchas, 2011).  
MORs are broadly expressed throughout the pain pathways. Their expression is 
enhanced in unmyelinated peptidergic fibers or thermonociceptors (Vetter et al., 2006; 
Chen and Pan, 2008; Bardoni et al., 2014) possibly involved in the control of postoperative 
pain. The presence of MOR in these afferent fibers also contributes to the development of 
opioid tolerance and hyperalgesia (Araldi et al., 2015; Corder et al., 2017; Araldi et al., 
2018). In the spinal dorsal horn, MOR is present in lamina I projection neurons and 
subpopulations of lamina II interneurons (Corder et al., 2017; Corder et al., 2018; Wang et 
al., 2018). In the setting of injury, spinal MORs are thought to promote long-lasting 
endogenous analgesia via increased constitutive activity (Corder et al., 2013) 
predominantly in central terminals of primary afferents (Severino et al., 2018). 
Spinal nociceptive transmission is highly modulated by MOR actions in supraspinal 
sites as well. Microinjections of MOR agonists or electrostimulation of the periaqueductal 
gray (PAG) and rostral ventromedial medulla (RVM), key modulatory areas in the 
brainstem, promotes robust antinociception. These effects are attributed to MOR inhibition 
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of excitatory (“on cells”) or disinhibition of inhibitory (“off cells”) in the RVM that send 
projections directly to the dorsal horn (Basbaum and Fields, 1984; Ossipov et al., 2014). 
Recent studies identified two distinct populations of “off cells” as GABAergic neurons co-
expressing Penk (proenkephalin) to inhibit nociceptive transmission in the dorsal horn, and 
a population of MOR-expressing cells that synapses with Penk-positive interneurons in the 
dorsal horn that modulates mechanonociception presynaptically (Francois et al., 2017; 
Corder et al., 2018). Therefore, MOR is a potent endogenous analgesic system promoting 
antinociceptive effects in different sites of the nervous system.   
2.7.3 Kappa opioid receptors  
  KOR is highly expressed in all levels of the pain neuroaxis and descending 
modulatory circuits. Under physiological conditions, KOR is activated upon binding of its 
endogenous peptide ligand, dynorphin (Goldstein et al., 1979; Goldstein et al., 1981; 
Fischli et al., 1982), which is expressed and released from nerve terminals in the CNS to 
selectively act on peripheral or central KORs (Chavkin et al., 1982; Wagner et al., 1991; 
Chavkin, 2013). Depending on the site of action, the activation of the KOR-dynorphin 
system is implicated in numerous physiological processes and pathologies including 
analgesia (Millan et al., 1985; Spampinato and Candeletti, 1985; Clemente et al., 2004; 
Auh and Ro, 2012; Snyder et al., 2018), paradoxical hyperalgesia (Tan-No et al., 2002; Lai 
et al., 2006; Luo et al., 2008), stress (Knoll and Carlezon, 2010; Chavkin, 2013; Xie et al., 
2017), mood disorders (Land et al., 2008; Carroll and Carlezon, 2013; Li et al., 2016), and 
reinstatement of drug seeking  (Sun et al., 2010; Jackson et al., 2015; Reed et al., 2018). 
When activated by dynorphin or exogenous full or partial agonists, KOR promotes 
analgesic effects via Gi/o signaling (Chavkin, 2011), while its aversive and psychomimetic 
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effects are mediated by activation of mitogen-activated protein kinase MAPK (Bruchas et 
al., 2007a; Land et al., 2008) in the brain. Emerging evidence indicates a possible 
dynorphin-independent KOR activation after stress (Polter et al., 2017) and injury 
(Walwyn et al., 2016). 
2.7.3.1 Peripheral 
In the periphery, KOR is present in free nerve terminals in the enteric mucosa and 
skin to regulate neuroendocrine, immune functions (Hedner and Cassuto, 1987), and pain 
(Joris et al., 1987; Stein et al., 1988; Moon et al., 2016; Snyder et al., 2018). In the setting 
of inflammation, endogenous opioids are released from immune cells in a P38 MAPK 
dependent process (Stein, 1991). Endogenous and exogenous opioids may penetrate the 
perineurial barrier of nociceptors after inflammation to interact with opioid receptors and 
promote analgesia (Stein, 1991; Antonijevic et al., 1995; Rittner et al., 2009). Alternatively, 
there is speculation that KOR agonists may interact with receptors expressed on immune 
cells (Snyder et al., 2018). The peripheral antinociceptive effects of KOR exogenous 
agonists are well characterized. KOR activation attenuates neurogenic inflammation via 
reduction of plasma extravasation and hyperemia induced by inflammatory mediators 
(Snyder et al., 2018).  Additionally, it decreases thermal (Joris et al., 1987),  and mechanical 
sensitivity after chronic inflammation (Auh and Ro, 2012). A recent study characterized 
the expression of KOR in peptidergic nociceptors in the skin and visceral tissues and 
implicated peripheral KOR in the modulation of mechanical pain associated with surgical 





2.7.3.2 Spinal Cord 
KOR is highly abundant in the superficial dorsal horn (lam. I and II) of the spinal 
cord (Harris and Drake, 2001; Harris et al., 2004). It is present in the central terminals of a 
subset of primary peptidergic afferent neurons in mice and humans, low threshold 
mechanoreceptors and the dorsal column (Snyder et al., 2018). The expression of KOR in 
projection and interneurons is not yet well characterized. KOR agonists delivered spinally 
elicit analgesia in several pain models (Milan, 1990) and suppress chloroquine induced-
itch (Kardon et al., 2014). Similarly, the release of dynorphin from interneurons located in 
the superficial dorsal horn reduce mechanical pain (Todd, 2017). Moreover, dynorphin 
peptide i.t. administration leads to analgesia in acute pain models, an effect that is mediated 
by KOR binding (Spampinato and Candeletti, 1985; Podvin et al., 2016).  
Conversely, in chronic inflammatory and nerve injury models dynorphin 
administration elicits hyperalgesia/allodynia via non-opioid pathways, possibly through 
direct or indirect interaction with NMDA or bradykinin receptors (Vanderah TW et al, 
1996; Tan-No K, et al., 2002; Lai et al., 2006, Luo MC et al., 2008). The effects of KOR 
agonists in spinal nociceptive plasticity (LTP) yielded mixed results; some studies failed 
to demonstrate an effect of KOR agonists in spinal field potentials (Buesa et al., 2008), 
while others found KOR inhibitory effects on C-evoked potentials (Sullivan and 
Dickenson, 1991) and voltage-gated Ca+2 currents (Snyder et al., 2018). Moreover, 
systemic Norbinaltorphimine (Nor-BNI) administration three weeks after surgical incision 
under remifentanil restored mechanical hyperalgesia in mice. In line with these results, 
spinal administration of long-lasting KOR antagonists also elicited hyperalgesia three 
weeks after intraplantar CFA injection in rodents, when the mechanical thresholds returned 
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to baseline levels. It is important to note that the long-lasting KOR antagonists used in the 
abovementioned studies have a delayed onset (Munro et al., 2012), off-target effects in 
MOR (Horan et al., 1992) in high dosages, and are thought to act indirectly on KOR 
through JNK-1 signaling, which in turn leads to KOR desensitization (Bruchas et al., 
2007b). Therefore, the precise effects of spinal KOR activation in chronic pain are still 
unresolved.  
Thus, throughout this work, we will investigate the effects of spinal KOR in chronic 
postoperative pain using primarily the selective reversible short-acting antagonist 
LY2456302 (currently known as CERC 501), which acts directly on KOR (Rorick-Kehn 
et al., 2014b). Moreover, the vast majority of animal research focuses on the KOR effects 
mediated by Gβγ or β-arrestin-independent signaling. Therefore, we further expand the 
literature evaluating antinociceptive effects of kappa in chronic pain via components of Gα 
(AC1 and cAMP) signaling.   
2.7.3.3 Brain 
KORs are expressed in multiple brain loci. The dynorphin-KOR system is 
implicated in the regulation of several brain psychopathologies. For example, KOR 
regulation of the mesocorticolimbic circuitry underlies the etiology of mood disorders, 
dysphoria and reinstatement of drug seeking (Cahill et al., 2014) through inhibition of 
monoaminergic centers at several sites (Lalanne et al., 2014). The amygdala is an important 
site for regulation of stress, and affective components of pain (Narita et al., 2006; Cahill et 
al., 2014; Xie et al., 2017), while the RVM is a key site of modulation in inflammatory 
pain. Microinjection of KOR agonist in the left central amygdala in rats “primed” with 
sumatriptan infusion reveals reduction of paw mechanical thresholds, which is reversed by 
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KOR blockers, implying pronociceptive actions of KOR (Xie et al., 2017; Navratilova et 
al., 2018). Conversely, microinjection of KOR agonists in the RVM reduces mechanical 
and thermal sensitization, effects that became more evident as inflammatory pain persists 
(Hurley and Hammond, 2000; Schepers et al., 2008b; Schepers et al., 2008a). Therefore, 
the modulatory effects of KOR systems in pain processing is dependent on the site of action 
and regulatory functions.   
Copyright © Lilian Custodio 2019 
35 
 
CHAPTER 3. Sex Differences in Kappa Opioid Receptor Inhibition               
of Latent Postoperative Pain 
This chapter is a similar version of the manuscript submitted to Neuropharmacology. 
Donahue R.R., Lambert J., Smith B., and Taylor B.K. are additional authors of the 
manuscript. 
3.1 Abstract 
Tissue injury induces an allostatic state of latent pain sensitization (LS) in the dorsal 
horn neuron that is opposed in part by mµ-opioid receptor constitutive activity. Blockade 
of this endogenous inhibitory activity with naltrexone or naloxone reveals LS as a 
reinstatement of mechanical hypersensitivity. However, naltrexone or naloxone also bind 
with significant affinity to delta and kappa opioid receptors. Therefore, to evaluate the 
specific contribution of mu, delta, and kappa opioid receptors to endogenous inhibition of 
LS, we performed plantar incision at the hindpaw, waited 21 days for the resolution of 
hyperalgesia, and then intrathecally injected subtype-selective antagonists. We found that 
neither of the two delta receptor-selective antagonists naltrindole (1µg) nor TIPP[Ψ] (1-
10µg) changed mechanical thresholds. By contrast, the mu receptor-selective antagonist 
CTOP (1-1000ng) dose-dependently reinstated mechanical allodynia, to a similar degree 
in male and female mice. Similarly, the kappa receptor-selective antagonists Nor-BNI (0.1-
10µg) and LY2456302 (0.1-10µg) reinstated mechanical allodynia. Furthermore, 
LY2456302 (10µg) increased the expression of phosphorylated signal-regulated kinase 
(pERK), a marker of central sensitization, in dorsal horn neurons but not glia. Sex studies 
revealed that a lower (0.3µg) but not higher dose (10µg) of LY2456302 reinstated 
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hypersensitivity to a greater degree in female as compared to male mice. Our results 
suggest that spinal MOR and KOR, but not DOR, maintain LS within a state of remission 
to reduce the intensity and duration of postoperative pain and that endogenous KOR but 
not MOR analgesia is greater in female mice. 
3.2 Introduction 
Tissue injury induces a sustained form of neuronal plasticity, termed latent 
sensitization (LS), that is kept within a state of remission by compensatory pain inhibitory 
systems that include opioid, neuropeptide Y and alpha2-adrenergic receptor signaling 
(Rivat et al., 2002; Campillo et al., 2011; Solway et al., 2011; Corder et al., 2013; Taylor 
and Corder, 2014; Walwyn et al., 2016). Long-lasting mechanisms of endogenous opioid 
receptor analgesia include mµ-opioid receptor constitutive activity (MORCA) (Corder et 
al., 2013; Walwyn et al., 2016); evidence for endogenous opioid inhibition of LS exists not 
only in mice and rats, but also in human experimental pain models (Pereira et al., 2015b; 
Pereira et al., 2015a). Some studies also indicate a contribution of delta-opioid receptor 
(DOR) and kappa-opioid receptors (KOR) (Campillo et al., 2011; Walwyn et al., 2016; Xie 
et al., 2017). However, these studies were limited to behavioral indices of pain and/or 
animals received prior administration of a different drug. To address these deficiencies, we 
performed plantar incision at the hindpaw, waited 21 days for the resolution of 
hyperalgesia, and then intrathecally injected multiple doses of multiple subtype-selective 
opioid receptor ligands. In addition to behavior, we also assessed touch-evoked changes in 
the expression of phosphorylated extracellular signal-regulated kinase (pERK), a marker 
of central sensitization of nociceptive neurons in the dorsal horn (Gao and Ji, 2009). 
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Numerous studies report sex differences in the ability of exogenous KOR ligands 
to modulate pain in both rodents (Mogil et al., 2003; Terner et al., 2003a; Terner et al., 
2003b; Sternberg et al., 2004; Lomas et al., 2007; Auh and Ro, 2012; Robinson et al., 2016) 
and humans (Gear et al., 1996a; Gear et al., 1996b; Pande et al., 1996b; Pande et al., 1996a; 
Gear et al., 1999). However, questions of sex differences in endogenous opioid receptor 
analgesia have not been rigorously studied. To address this gap, we investigated whether 
sex is a main factor in endogenous spinal MOR- and KOR-mediated inhibition of LS by 
testing both male and female mice.  
3.3 Materials and Methods 
3.3.1 Subjects  
Experiments were carried out in 8-12 weeks old male and female C57Bl/6 mice 
(Charles Rivers Laboratories, Inc, Wilmington, MA). Mice were housed maximum 5 same-
sex littermates per cage in a temperature and humidity-controlled room (14:10hr light-dark 
cycle, lights on at 6:00 am) with ad libitum access to food and water.  The Institutional 
Animal Care and Use Committee at the University of Kentucky, protocol (#2017-2768), 
approved all procedures following American Veterinary Medical Association guidelines. 
Mice were acclimated to the colony housing room for several days and then handled for 2 
days by the experimenter before the initiation of the studies. 
3.3.2 Plantar Incision Model of Postoperative Pain 
Post-operative pain was induced by longitudinal incision of the plantaris muscle, as 
previously described (Pogatzki and Raja, 2003; Jang et al., 2011). Under isoflurane 
anesthesia (5% induction and 1.5-2% maintenance, via a nose cone) and antisepsis of the 
left hind paw with Chlorascrub® then alcohol, a #11 scalpel blade was used to perform a 
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5mm through the skin and fascia using, beginning 2mm from the proximal edge of the heel 
extending towards the digits. The underlying muscle was raised with curved forceps, 
extended 4 mm and incised longitudinally, leaving the origin and insertion of the muscle 
intact. The overlying skin was closed with synthetic 5-0 sutures (PDS*II, Ethicon), 
followed by application of antibiotic ointment was applied. Surgery was typically 
completed within 5-10min. Sutures were removed on the post-operative day 10.  Sham 
controls received anesthesia but no surgical incision.   
3.3.3 Direct Intrathecal (i.t.) Drug Delivery 
As previously described (Fairbanks, 2003), non-anaesthetized mice were lightly 
restrained in a towel, and a 30G x1/2 needle (Becton Dickinson) attached to a 25-µl 
Hamilton micro syringe, was inserted into the subarachnoid space between the L5/L6 
vertebrae. The needle was angled about 30-45 degrees with the horizontal plane and 
slightly advanced until reflexive tail flick was confirmed, then 5 µl of drug or vehicle was 
slowly administered. The needle was held in place for 30sec, to ensure the solution fully 
enters the spinal canal, withdrawn, and then the mouse was returned to its testing chamber. 
3.3.4 Drug Dosing 
All Drugs or vehicle were intrathecally injected in a 5 µl bolus. The MOR selective 
ligand D-Phe-c[Cys-Tyr-Trp-Orn-Thr-Pen]-Thr-NH2 (CTOP, Cat.#1578 Tocris) was 
dissolved in sterile saline (0.9%NaCl) and injected at doses of 1 – 1000ng (Gendron et al., 
2007; Corder et al., 2013). Based on these doses we established dose response curves. The 
DOR-selective ligand Naltrindole HCL (Sigma-Aldrich N115) was dissolved in sterile 
saline and injected at doses of 0.1-10µg (Scherrer et al., 2009), H-Tyr-TicΨ [CH2-NH] 
Phe-Phe-OH (TIPP[Ψ], gift from NIDA Drug Supply Program) was sonicated in ddH20 at 
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30°C for 30 minutes and injected at doses of 1-10µg (Riba et al., 2002b; Riba et al., 2002a). 
Doses of naltrindole equal to or greater than 10 μg and TIPP[Ψ] at 20 μg elicited adverse 
effects such as itching, licking and tail biting, so we limited their use to a high dose of 1 
μg of naltrindole and 10 μg of TIPP[Ψ]. The KOR-selective ligand norbinaltorphimine 
dihydrochloride (Nor-BNI, 0347 Tocris) was dissolved in saline and injected at doses of 
0.1-10µg. For Figures 3.4 and 3.6, LY2456302 (Rorick-Kehn et al., 2014a; Rorick-Kehn 
et al., 2014b) was obtained from the NIDA Drug Supply Program, sonicated in ddH20 at 
30°C for 30 minutes, and 0.1-10µg was injected. For Figures 3.6, 3.7 and 3.8, LY2456302 
was obtained from Med Chem Express, dissolved 1:1:8 in EtOH: Alkamuls EL-620, 
Rhodia, Cranbury, NJ: saline, and injected at dose of 10 µg.  
Testing began at day 21 after surgery to allow for mechanical thresholds to return 
to pre-incision baseline levels. At this time, animals were assigned to experimental groups 
by a laboratory colleague (RRD, WF) who kept the code until the experiments were 
completed. On day 21, some animals received appropriate drug, or vehicle. After a seven-
day washout, animals given drug on day 21 were given vehicle or higher dose of that same 
drug on day 28. Conversely, animals given vehicle on day 21 were given drug on day 28. 
This cross-over design was not used with the KOR ligands due to their extended half-lives. 
3.3.5 Pain-Like Behavioral Assessment: Stimulus-Evoked 
All animals were acclimated in a temperature and light controlled room within 
individual Plexiglas boxes placed on the top of a stainless-steel mesh platform for 30 to 60 
min prior to behavioral testing. Mechanical thresholds were assessed using an incremental 
set of 8 von Frey monofilaments (Stoelting, Illinois), ranging in gram force from 0.008g to 
6g. The filaments were applied perpendicularly to the ventral surface of the hindpaw lateral 
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to the suture site with enough force to engender slight bending of the filament. A positive 
response was characterized as a rapid withdrawal of the paw away from the stimulus fiber 
within 5s. Left and right hindpaws were tested alternately. Using the up-down method 
(Chaplan et al., 1994),  response patterns were logarithmically converted into 50% 
withdrawal thresholds (in gram force). As previously described, animals were randomly 
assigned to experimental groups in all studies.  Investigators (LCP and RRD), blinded to 
experimental groups by a research associate, and conducted all behavioral experiments. 
3.3.6 Touched-evoked Phosphorylated Extracellular Signal-Regulated Kinase 
(pERK)  
As previously described (Corder et al., 2013), 21 days after surgery mice received 
either vehicle or LY2456302 (10µg). Two hours after injection, mice were lightly 
anesthetized with isoflurane (1.5%), and the ventral surface of the ipsilateral hindpaw was 
mechanically stimulated with gentle 2-second stroke with a cotton swab from heel to toe. 
This was repeated every 5s for 5min. After an additional 5 min pause, mice were deeply 
anesthetized with isoflurane and transcardially perfused with cold 0.01M phosphate buffer 
saline (PBS, Fischer Scientific) /heparin buffer (10,000 USP units/L), followed by 10% 
phosphate formalin buffer. Lumbar spinal cords were harvested and post-fixed in the same 
fixative overnight at 4oC, and then cryoprotected with 30%sucrose until total submersion 
(1-3 days).  
3.3.7 Histology and Immunohistochemistry 
Transverse sections (30μm) from L3-L5 were obtained on a sliding microtome 
(Leica, SM 2000R). A series of sections, each 240µ apart, was washed in 0.01M PBS, 
blocked in 3% normal serum (goat or donkey; Gemini Bioproducts), containing 0.3% 
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Triton X-100 (Sigma Aldrich) in 0.01M PBS for 1h, and  then incubated with primary 
rabbit antibody anti-phosphorylated-ERK ½ antiserum (1:800, Cell Signaling) at 4oC for 
36 hours on a shaker (Fig.3.4, 3.6 and 3.7), or goat anti- -Iba1 (isoforms 1 and 3) (1:500, 
Sigma Aldrich), and/or chicken anti-GFAP (1:1000, Abcam) at 4oC overnight. The 
following day, sections were again washed in 0.01M PBS and incubated for 1h at room 
temperature with secondary conjugated antibodies (1:1000, Invitrogen: donkey anti-rabbit 
Alexa Fluor 568, donkey anti-goat Alexa Fluor 488, goat anti-rabbit Alexa Fluor 568, 
and/or goat anti-chicken Alexa Fluor 488. For neuronal co-staining, FITC-conjugated 
mouse NeuN (MAB377X 1:500, EMD Millipore) was incubated for 1h at room 
temperature (Fig.3.8). The sections were washed in 0.01M phosphate buffer, mounted and 
cover slipped with mounting medium with DAPI (Vectashield, Vector laboratory). At least 
five good quality sections from segment L4 were selected from each subject for 
microscopy. 
3.3.8 Microscopy 
Fluorescence Microscopy. For quantification of pERK immunoreactivity, low 
magnification images taken with Nikon TE-2000 microscope equipped with a 10X 
objective were captured and analyses with NIS-Elements Software AR 4.13.05. An 
examiner blinded to treatment and sex counted the number of positive pERK cells in 
laminae I-II and III-V.  
Confocal Microscopy. For double-label immunohistochemistry, confocal images 
were acquired with a Nikon A1 Confocal Microscope System equipped with a 60X oil-
immersion objective (numerical aperture 1.49) located in the Microscopy Core at the 
Department of Biochemistry at the University of Kentucky Biomedical Biological Sciences 
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Research Building. Laser excitation and emission windows for the different fluorophores 
were as follows: Alexa Fluor 568 (Cy3) – excitation 543.5 nm, emission 543-633 nm, 
Alexa Fluor 488 (EGFP) – excitation 488nm, emission 483-543nm, and DAPI - excitation 
405nm, emission 423-483nm. Z-stacks images were obtained with 0.5mm slice thickness. 
Images were processed using Nikon NIS-elements confocal software AR 4.30.02. 
3.3.9 Statistical Analysis 
Mechanical thresholds are summarized as mean values quoted with the 
corresponding standard error (mean ± SEM). The effects of Drug and Time were analyzed 
by two-way analysis of variance (ANOVA), followed by Bonferroni multiple correction 
tests. Data were then re-plotted as area under the curve using the trapezoidal method and 
integrative thresholds were analyzed using one-way or two-way ANOVA as appropriate, 
followed by Bonferroni tests using Prism 8 (GraphPad, La Jolla, CA). Non-linear 
regression analyses of Maximum Possible Effect (%MPE) were used to determine the 
ED50 for each drug. %MPE was calculated as follows: % MPE = 100* (post-injection 
threshold – preinjection threshold) / (post-injury threshold – pre-injection threshold). For 
Figures 3.5 and 3.6, sex differences in mechanical threshold were analyzed using repeated 
measures three-way ANOVA, with Sex and Drug analyzed as between-subject factors, and 
Time analyzed as a within-subject factor. To assess the Drug by Sex interactions, linear 
mixed models were used with random intercepts and time slopes for each animal. Pairwise 
time points were individually analyzed using the mixed model approach to increase the 
power to detect Sex by Drug interactions. Linear Mixed models were fit using the lme4 
V1.1-15 package in R V3.4.3 (R software). The criterion for the level of significance was 
set at P ≤ 0.05 (). All graphs were created using Prism 8 (GraphPad, La Jolla, CA).  
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3.4 Rationale and Results 
3.4.1 MOR and KOR, but not DOR opioid receptor signaling provide 
postoperative endogenous analgesia 
To determine which opioid receptors provide endogenous analgesia in the setting 
of LS, we performed plantar incision, waited 21 days for mechanical hypersensitivity to 
completely resolve, and then to these mice, termed PIM 21d mice, we intrathecally injected 
opioid receptor subtype-selective antagonists. 
Mu opioid receptor. As illustrated in Figure 3.1A, intrathecal administration of the 
selective MOR antagonist CTOP in male PIM 21d mice dose-dependently reinstated 
mechanical hypersensitivity as compared to saline (F (28,217) =9.43, p<0.0001). The 
pronociceptive effect of CTOP was robust, peaking at 30 min (0.14  0.03g, 0.08  0.02g 
at 1ng and 1000ng respectively), and lasted for at least 180 min. As illustrated in Figure 
3.1B, area under the curve analysis (AUC 30-180min) illustrates concentration-dependent 
effects of CTOP (F (4, 29) =41.3, p<0.0001).  As illustrated in Figure 3.1C, conversion of 
the 30 min timepointn data to %MPE yielded an ED50 value of 1.84 ng. 
Delta opioid receptor. As illustrated in Figure 3.2A, this dose of naltrindole did not 
change mechanical hypersensitivity in male PIM 21d mice (F (6,156) =2.01, p=0.07). We 
then tested an alternative DOR antagonist (TIPP[Ψ] 1µg-10µg), and Fig 2B similarly no 
effect on mechanical hypersensitivity (F (12,102) =0.35, p=0.97).  
Kappa opioid receptor. We used either the prototypical KOR antagonist nor-BNI 
or the shorter-acting and highly selective KOR antagonist LY24506302 due to its favorable 
pharmacokinetic properties compared to nor-BNI (Munro et al., 2012; Rorick-Kehn et al., 
2014b). As illustrated in Figures 3.3A-B, the selective KOR antagonists nor-BNI (0.1-
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10µg) or LY2456302 (0.1-10µg) produced a dose-dependent reinstatement of mechanical 
hypersensitivity compared to saline- (Nor-BNI, F (27,216) =3.73, p<0.0001 and 
LY2456302, F (33,286) =5.63, p<0.0001, Fig. 3.3A, D). The effect on hyperalgesia of both 
Drugs peaked at 3h (Nor-BNI, 0.19  0.06g and LY2456302, 0.30  0.04g) and lasted at 
least 72h. As illustrated in Figures 3.3 C-D, AUC analysis (1-72h) yielded F values of (F 
(3, 24) =12.90, p<0.0001) Nor-BNI and (F (3, 26) =20.37, p<0.0001) for LY2456302.  As 
illustrated in Figures 3.3 E-F, focus on the 3h timepoint yielded ED50 values of 0.87µg for 











Figure 3.1. Spinal MOR blockade reinstates mechanical hypersensitivity in a dose 
dependent manner.  
The MOR selective antagonist CTOP was intrathecally (i.t.) administered 21d after plantar 
incision in C57/Bl6 male mice. (A) Time course of mechanical hypersensitivity after CTOP 
(1ng-1000ng) administration produces reinstatement of mechanical hypersensitivity in a 
dose-dependent manner (n=8 per dose). (B) The area under the curve (AUC, 30-180 min) 
illustrates the concentration-dependent actions of CTOP on mechanical hypersensitivity.  
(C) Dose-response analysis of the data at 0.5h after injection revealed an ED50 of 1.84ng. 
MPE: maximum possible effect. p<0.05 CTOP vs. vehicle. BL = baseline behavior prior 












Figure 3.2. Spinal DOR selective antagonists do not reinstate mechanical 
hypersensitivity.  
DOR selective antagonists Naltrindole (A) and TIPP(Ψ) (B) were administered i.t. 21d after 
plantar incision in C57Bl6 mice. Time course of mechanical hypersensitivity after 
Naltrindole (1ug-10ug), and TIPP(Ψ) (1ug-10ug) administration show no significant 
reinstatement of mechanical hypersensitivity (n=10-18 per dose Naltrindole p=0.07, n=6-
8 per dose TIPP(Ψ), p=0.9). BL = baseline behavior prior to drug administration. 
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Figure 3.3. Spinal KOR blockade reinstates mechanical hypersensitivity in a dose-
dependent manner.  
The KOR selective antagonists Nor-BNI (A) and LY2456302 (B) were intrathecally (i.t.) 
administered 21d after plantar incision in C5/Bl6 male mice. Time course of mechanical 
hypersensitivity after Nor-BNI (0.1ug-10ug; n=5-10 per dose) and LY2456302 (0.1ug-
10ug; n=6-8 per dose) administration exhibited robust reinstatement of mechanical 
hyperalgesia in a dose-dependent manner. (C-D) Area under the curve (Nor-BNI AUC, 
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1-72h; LY AUC, 1-120h) illustrates the concentration-dependent actions of both drugs on 
mechanical hypersensitivity. (E-F) Dose-response analysis of the data at 3h revealed an 
ED50 of 0.87ug for Nor-BNI, and an ED50 of 1.04ug for LY2456302 for mechanical 
hypersensitivity. MPE: maximum possible effect. p<0.05 Ly/Nor-BNI vs. vehicle. BL 
















3.4.2 Spinal kappa opioid antagonism modulates latent nociceptive 
sensitization in the dorsal horn 
Our pharmacological behavior experiments demonstrated that spinally delivered 
KOR antagonists produce reinstatement of hyperalgesia 21 days after surgical paw 
incision. These findings suggest that similar to MOR, KORs exert tonic inhibition that 
opposes pronociceptive signals within the spinal pathways, preserving LS within a state of 
remission. Thus, to determine whether KOR activity reduces the cellular manifestations of 
latent sensitization after incision, we evaluated the light-touch-evoked expression of 
pERK, a well-recognized marker of central sensitization during pathological pain (Gao and 
Ji, 2009; Ji et al., 2009), in the superficial (I-II) and deep laminae (III-V) of the dorsal horn. 
We assessed immunohistochemical changes in pERK expression in the dorsal horn during 
the peak of drug activity, 2h after LY or saline i.t. delivery. Intraplantar capsaicin was used 
as a positive control as it activates C-afferent fibers markedly increasing the 
phosphorylation of ERK in the superficial dorsal horn (Kawasaki et al., 2004). We 
quantified the number of pERK-positive cells as a marker of activation of the nociceptive 
sensitization pathway. We found that compared to controls, light-touch of the injured 
hindpaw increased pERK cell profiles 21 days after plantar incision in the ipsilateral dorsal 
horn (4.89 ± 0.48 vs. 0.77 ± 0.11, p<0.0001; 1.36 ± 0.22 vs. 0.22 ± 0.22, p=0.3) LY vs. 
vehicle in the ipsilateral lam I-II and III-V respectively. (4.89 ± 0.48 vs. 1.52 ± 0.16) LY 
ipsilateral vs. contralateral paw. F (3, 16) = 16.83, p<0.0001) 2 hours after KOR blockade 
(Figure 3.4 B-E). 
51 
Figure 3.4. KOR spinal blockade via LY2456302 increased light-touch evoked 
positive pERK cells in the dorsal horn.  
The number of positive pERK cell profiles in the dorsal horn (A) superficial (I-II) and deep 
(III-V) lamina the Rexed is increased after intrathecal administration of (B) LY (10ug) and 
(C) capsaicin (positive control) compared (D) to vehicle administration in 21d
postoperative male mice. (E-F) Histogram showing light touch-induced pERK-positive 
cells are significantly higher in LY treated mice compared to controls in the side ipsilateral 
to the injury (n=3-4, 4-5 slices per animal). p<0.05 LY vs. vehicle, # p<0.05 ipsilateral 
vs. contralateral. Scale bar 100m. Figure (A) adapted from Corder et al, 2013. 
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3.4.3 Postoperative endogenous KOR Analgesia is enhanced in female mice 
As illustrated in Figures 3.5 and 3.6, plantar incision produced a robust decrease 
in mechanical threshold on the paw ipsilateral but not contralateral to injury. The time 
course of mechanical hypersensitivity did not significantly differ between male and female 
mice (p>0.05) when tested at either the paw ipsilateral to injury (Fig 3.5.A-B and 3.6.A-B) 
or contralateral to injury (Fig 3.5C-D and 3.6C-D). Thresholds returned to baseline by post-
operative day 21 in each sex. These results are consistent with previous findings in mouse 
incision models (Banik et al., 2006). 
Postoperative patients exhibit sex differences in endogenous opioid inhibition of 
pain (Fillingim and Gear, 2004). We previously reported that inverse agonist-induced 
reinstatement of mechanical hyperalgesia and facial grimace in the CFA model of LS did 
not differ between male and female mice (Corder et al., 2013); however, these studies were 
limited to to a single dose of naltrexone which can interact with mu, delta, and kappa opioid 
receptors. Therefore, we asked whether low or high doses of CTOP or LY2456302, as 
determined by the dose-response curves in Figures 3.1 and 3.3, would yield sex differences 
in mechanical thresholds after injection in PIM 21d male and female mice.  
Mu opioid receptor. Our results in male mice demonstrated that both CTOP 100ng and 
1000ng dose produced robust hyperalgesia in PIM 21d male mice (Figure 3.1A), which 
were close to the maximum efficacy (Figure 3.1C). Thus, we selected 100ng for further 
studies. As illustrated in Figure 3.5A, a high dose of CTOP (100ng) but not vehicle 
produced robust hyperalgesia in PIM 21 male and female mice at the ipsilateral side (Main 
Drug Effect F (1,90)= 57.25, p<0.0001; Time vs. Sex vs. Drug Interaction F (5,90)= 0.19, 
p=0.96). As illustrated in Figure 3.5B, CTOP (100 ng) also produced a robust hyperalgesia 
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at the contralateral side that did not differ between the sexes (Main Drug Effect F (1, 54) 
=48.80, p<0.0001; Time vs. Sex vs. Drug Interaction F (5, 54)=0.87, p=0.50). As illustrated 
in Figure 3.5C, AUC analysis confirmed that CTOP (100 ng)-induced reinstatement of 
hyperalgesia did not differ between the sexes (F (3, 43) =0.90, p=0.78).  
Since this relatively high dose of CTOP may have produced a floor effect that could 
have masked a sex differences, we repeated this study using the lowest effective dose in 
males (Figure 1). As illustrated in Figure 3.5D-F, low-dose CTOP reinstated hyperalgesia 
(main Drug effect F (1,44) =4.40, p =0.04 ipsilateral; F (1,14) = 5.99, p=0.02 contralateral) 
to a similar degree in male and female mice (Time vs. Sex vs. Drug Interaction F (5,220) 
=0.24, p=0.94, Fig. 3.5B; Time vs Sex vs. Drug Interaction F (5,70) =0.34, p=0.88), AUC 
F(3, 58) =0.08, p =0.1 (Figure 3.5.F). 
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Figure 3.5. Spinal MOR blockade reinstates mechanical hypersensitivity equally in 
male and female mice.  
(A-B) Time course of mechanical thresholds at baseline (BL), 1, 3, 5, 7,14 and 21-28 days 
in male or female C57Bl/6 male, and then after intrathecal injection of CTOP at a dose of 
100ng at the paw ipsilateral (A) or contralateral (B) to plantar incision. (C) Analysis of 
area under the curve (AUC, 0.5-2h) illustrates that CTOP (100ng) reinstated mechanical 
hypersensitivity at both the ipsilateral and contralateral hindpaws equally in males and 
females. (D-E) Time course of mechanical thresholds at baseline (BL), 1, 3, 5, 7, 14 and 
21-28 days in male or female C57Bl/6 male, and then after intrathecal injection of CTOP
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at a dose of 1ng at the paw ipsilateral (D) or contralateral (E) to plantar incision. (F) 
Analysis of area under the curve (AUC, 0.5-2h) illustrates that CTOP (1.0ng) reinstated 
mechanical hypersensitivity at both the ipsilateral and contralateral hindpaws equally in 
males and females. n=4-10 per group. p<0.05 CTOP vs. vehicle. Data are represented 
as mean +/- SEM. 
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Kappa opioid receptor. Next, we investigated whether sex differences exist in endogenous 
KOR-mediated inhibition of postoperative pain in our LS model.  We chose not only the 
prototypical KOR  antagonist  (inhibitor) Nor-BNI, but due to its delayed onset and 
duration of action which can last up to four weeks (Horan et al., 1992; Munro et al., 2012), 
we also selected the shorter-acting KOR antagonist LY24506302 due to its favorable 
pharmacokinetic properties compared to nor-BNI (Rorick-Kehn et al., 2014a; Rorick-Kehn 
et al., 2014b). As illustrated in Figure 3.6A-B, a relatively high dose of LY24506302 
(10µg) reinstated mechanical hypersensitivity compared to saline in male and female mice 
at the sides both ipsilateral (F (1, 21) = 21.80, p<0.0001) and contralateral (F (1, 21) = 
14.44, p=0.001) to plantar incision. However, the degree of reinstatement did not differ 
between the sexes (Time vs. Sex vs. Drug interaction F (8,168) = 0.13, p = 0.99, 5A; F 
(8,168) = 0.25, p = 0.25, 5D), and this is further illustrated in Figure 3.6C by area under 
the curve analysis across the 1 to 120 hr time points (F (3, 43) = 0.356, p=0.78).   
Since this relatively high dose of LY24506302 may have produced a floor effect that 
could have masked a sex difference, we repeated this study using a lower dose of 0.3 µg as 
suggested by the dose-response curve in Figures 3.3D-F. As illustrated in Figure 3.6D, 
LY2456302 (0.3 µg) reinstated hyperalgesia at the side ipsilateral to incision in both male 
and female mice, and importantly to a greater extent in female mice (Bonferroni posthoc 
test p<0.05). Figure 3.6E illustrates a smaller effect on the contralateral side that did not 
differ between sexes. Further analysis in Figure 3.6F illustrates that female PIM 21d mice 
exhibited greater mechanical hyperalgesia at the peak of LY-induced reinstatement at the 
2-4h time points (Sex vs. Drug Interaction, Satterthwaite: p-value=0.041).
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Figure 3.6. LY2456302-induced reinstatement of mechanical hypersensitivity is 
greater in females.  
(A-B) Time course of mechanical thresholds at baseline (BL), 1, 3,5, 7, 14 and 21-28 days 
in male or female C57Bl/6 male, and then after intrathecal injection of LY2456302 at a 
dose of 10μg at the paw ipsilateral (A) or contralateral (B) to plantar incision. (C) Analysis 
of area under the curve (AUC, 0.5-2h) illustrates that LY2456302 (10μg) reinstated 
mechanical hypersensitivity at both the ipsilateral and contralateral hindpaws equally in 
males and females. (D-E) Time course of mechanical thresholds at baseline (BL), 1, 3, 5, 
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7, 14 and 21-28 days in male or female C57Bl/6male, and then after intrathecal injection 
of LY2456302 at a dose of 0.3μg at the paw ipsilateral (D) or contralateral (E) to plantar 
incision. (F) Analysis of area under the curve (AUC, 0.5-2h) illustrates that LY2456302 
(0.3μg) reinstated mechanical hypersensitivity at both the ipsilateral and contralateral 
hindpaws equally in males and females. n=6-8 per group. p<0.05 LY2456302 vs. 
vehicle, #p<0.05 male vs. female. Data are represented as mean +/- SEM. 
59 
3.4.4 Tonic KOR inhibition of dorsal horn neuron activity is enhanced in 
female mice 
We previously reported that MORCA inhibits long-lasting sensitization of dorsal 
horn neurons induced by cutaneous inflammation (Corder et al., 2013). To begin to address 
whether KOR inhibits neuronal activity as well, we evaluated light touch-evoked 
expression of pERK in the superficial (I-II) and deep laminae (III-V) of the dorsal horn, 
two hours after intrathecal administration of LY2456302 or saline in male and female mice, 
21 days after either sham or plantar incision surgery. As illustrated in Figures 3.7A-B, D-
E, G-H, light touch was associated with only a small number of pERK-positive profiles in 
sham controls that received LY2456302 or vehicle treated mice. By contrast, Figures 3.7C, 
3.7F, and 3.7G illustrate that LY2456302 evoked a larger number of pERK+ profiles in 
PIM 21d mice at both superficial lamina I-II (F (5,23) = 1.61, p<0.001) and deeper laminae 
III-V (F (5,44) = 6.60, p=0.001). Importantly, LY2456302 was associated with
significantly more pERK+ profiles in laminae I-II in females as compared to males 
(p<0.05). p-ERK can be expressed on neurons, astrocytes, and microglia (Ji et al., 2009). 
To determine the cell type(s) that express pERK after LY2456302, we co-labelled with 
NeuN, GFAP, and Iba1. As illustrated in Figure 3.8, confocal microscopy revealed that 
pERK was expressed exclusively in NeuN-positive cells in laminae I–V of the dorsal horn 
obtained from female (Figures 3.8A-U) or male (Figures 3.8A’-U’) mice.  
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Figure 3.7. LY2456302-evoked pERK+ cells in the dorsal horn is greater in female 
mice. 
Representative photomicrographs of light touch-evoked pERK-immunoreactivity in L4 
lumbar sections from (A-C) female or (D-F) male mice, 21 days after sham surgery plus 
10µg LY2456302 (A, D), plantar incision plus vehicle (B, E), or plantar incision plus 10µg 
LY2456302 (C, F). (G-H) Quantification of mean number of touch-evoked pERK+ 
profiles in lamina I-II (G) or lamina III-V (H).  Data represent mean +/- SEM. ★p<0.05. 
LY2456302 vs. vehicle and sham incision. *p<0.05 LY2456302 vs. shams. # p<0.05 n= 4-






Figure 3.8. Touch-evoked pERK in the dorsal horn is co-localized exclusively with 
neurons.   
To determine whether KOR blockade evoked pERK expression in neurons, microglia, or 
astrocytes, we co-stained with NeuN, Iba1, or GFAP, respectively. Representative 
transverse lumbar (L4) spinal cord sections (30μm) from postoperative-21d mice 2h after 
intrathecal delivery of LY2456302 (10μg) and an ipsilateral light touch paw stimulation. 
Sections from females were co-labelled with pERK (A, C, D, G, H, J, K, N, O, Q, R and 





































































N, T-U). Sections from males were co-labelled with pERK (A’, C’,  D’,  G’, H’, J’,  K’, 
N’, O’,Q’,  R’ and U’), and NeuN (B’-C’, E’,G’), GFAP (I’-J’, L’,N’), or Iba-1 (P’-Q’, S’-
U’). DAPI (F’-G’, M’-N’, T’-U’). Arrows indicate pERK co-labeling. Light microscopic 
images in the left three columns were taken with a 10X objective, while confocal images 
in the right four columns were taken with a 60x objective. Scale bars: 50 μm. 
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3.5 Discussion 
3.5.1 Tonic MOR activity provides long-lasting inhibition of 
postoperative pain 
Tissue injury induces latent pain sensitization (i.e., LS) that is mediated in part by 
NMDA receptors, AMPA receptors, and adenylyl cyclase 1 signaling mechanisms in the 
dorsal horn (Corder et al., 2013; Taylor et al., 2019). These pronociceptive mechanisms 
are kept within remission by opposing pain inhibitory mechanisms (Solway et al., 2011; 
Corder et al., 2013; Walwyn et al., 2016; Fu et al., 2019) that include MORCA  (Corder et 
al., 2013; Walwyn et al., 2016). Evidence for the contribution of MOR comes in part from 
behavioral pharmacology studies using MOR-selective inhibitors. For example, when 
administered 21 days after the intraplantar injection of complete Freund’s adjuvant (after 
the resolution of initial hyperalgesia), intrathecal administration of a single dose of CTOP 
reinstated hyperalgesia (Corder et al., 2013). The current results not only extend these 
findings to the plantar incision model of postoperative pain, but also demonstrate a dose-
response curve with an ED50 value of approximately 2 ng. 
3.5.2 Spinal DORs do not provide long-lasting inhibition of postoperative pain 
Selective DOR activation inhibits  mechanical hypersensitivity associated with 
injury (Scherrer et al., 2009; Gaveriaux-Ruff et al., 2011; Bardoni et al., 2014) either 
through heterodimerization or synergistic interactions with MOR (Gomes et al., 2000; 
Hurley and Hammond, 2000; Gendron et al., 2007; Al-Hasani and Bruchas, 2011) or via 
autonomous mechanisms in distinct populations of spinal neurons, different than those that 
express MOR (Wang et al., 2018). In contrast to these studies using exogenous application 
of DOR agonists to inhibit early inflammatory pain, the current studies tested the 
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hypothesis that endogenous activation of DOR inhibits the longer-lasting vulnerability to 
inflammatory pain associated with LS. However, neither of the DOR antagonists that we 
used, naltrindole nor TIPP[Ψ], significantly changed mechanical threshold when 
administered during the remission phase of LS.  
Our DOR results are not consistent with Walwyn and colleagues who reported that 
subcutaneous administration of naltrindole reinstated hyperalgesia in a mouse CFA model 
of LS, and that either intrathecal or subcutaneous naltrindole reinstated hyperalgesia in a 
rat CFA model of LS (Walwyn et al., 2016). One possibility for the differences observed 
in the latter study and ours is that we tested the animals at a later time point after DOR 
administration. However, the reinstatement observed in the latter study was very short-
lasting and induced at an earlier time point (15 min after i.t. administration) in both 
experimental and control groups. Thus, confounders such as anxiety and sensitization of 
the subjects from repeated pharmacological experiments in the same animal could not be 
ruled out. Albeit, it is fundamentally interesting to speculate here that the plantar incision 
model and the CFA model (Walwyn et al., 2016) could induce LS via different receptors 
or mechanisms. 
In summary, our data suggest that DOR inhibitors do not reinstate hyperalgesia, 
and thus we conclude that spinal DORs do not provide long-lasting inhibition in our model 
of postoperative latent pain sensitization. Since our studies were limited to the intrathecal 
route of administration future studies are needed to investigate the role of endogenous 
DORs expressed at peripheral terminals of primary afferent neurons (Scherrer et al., 2009) 
or supraspinal sites involved in the descending inhibition of spinal transmission (Hurley 
and Hammond, 2000).   
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3.5.3 Tonic KOR activity provides long-lasting inhibition of postoperative pain 
The current results demonstrate that the kappa receptor-selective inhibitors nor- 
BNI and LY2456302 dose-dependently reinstated behavioral signs of postoperative pain, 
and LY2456302 increased the stimulus-evoked expression of pERK, a marker of central 
sensitization, in dorsal horn neurons but not glia. Our results are consistent with and extend 
previous studies that suggest a contribution of endogenous KOR to the inhibition of 
hyperalgesia. For example, systemic administration of nor-BNI reinstated hyperalgesia 
after paw incision performed under remifentanil in the mouse (Campillo et al., 2011) 
Furthermore, Marvizon and colleagues reported that nor-BNI reinstated mechanical 
hyperalgesia in the CFA model of LS (Walwyn et al., 2016). Prodynorphin deficient mice 
also responded with reinstatement of mechanical hyperalgesia, consistent with the 
hypothesis that, like MORCA, inflammation leads to constitutive activity at KOR (Walwyn 
et al., 2016). Therefore, in the current studies of LS, we have been careful to describe nor-
BNI and LY2456302 as KOR inhibitors, since we do not yet know whether their behavior 
is indicative of inverse agonism and ligand-independent constitutive activity, or 
antagonism and ligand-dependent activity. Albeit, our findings indicate that LS is 
maintained in remission by tonic KOR activity at the dorsal horn.  
In addition to the spinal sites of action suggested by our intrathecal injection 
studies, peripheral and supraspinal sites may also contribute to endogenous KOR inhibition 
of LS. Regarding peripheral sites, KOR is expressed in the nerve terminals of peptidergic 
populations of primary afferent neurons arising from the skin, viscera, and synovial tissues, 
and KOR signaling inhibits nociceptor sensitization and pain (Labuz et al., 2007; Cunha et 
al., 2012; Moon et al., 2016; Snyder et al., 2018). A recent study indicated that peripherally-
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restricted KOR agonists markedly reduced mechanical hyperalgesia at the early 
inflammatory phase of plantar incision (Snyder et al., 2018), implicating peripheral KOR 
as a major modulator of acute postoperative pain. Regarding supraspinal sites, 
microinjection of KOR agonists into the rostral ventral medulla activated descending 
modulatory neurons to inhibit nociception (Hurley and Hammond, 2000; Schepers et al., 
2008b; Schepers et al., 2008a) . Furthermore, the current study (Fig 3.6.) demonstrated that 
KOR inhibitors reinstate hyperalgesia not only at the side ipsilateral to injury but also at 
the contralateral side, thus further implicating supraspinal modulation of LS as previously 
proposed for MOR (Corder et al., 2013) and suggested by the current CTOP results (Fig 
3.5). 
KOR inhibitors produce not only hyperalgesia as in the current studies, but also 
antihyperalgesia in other studies. For example, in rats primed with sumatriptan or morphine 
infusion, delivery of KOR inhibitors in the central amygdala prevented acute stress-
induced hyperalgesia. In these studies, the pronociceptive effects of KOR were elicited 
from a descendent modulatory circuit from the right amygdala via MAPK signaling (Xie 
et al., 2017). Furthermore, KOR in the central nucleus of the amygdala promotes behaviors 
suggestive of disinhibition, aversiveness, anxiety (Narita et al., 2006) and pain facilitation 
(Navratilova et al., 2018). Thus, we propose that the direction of effect depends on the site 
of modulation, with KOR activation at the central terminals of primary afferent and 
intrinsic dorsal horn neurons leading to pain inhibition, while KOR activation at certain 
brain sites seems to cause pain. 
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3.5.4 Sex differences in postoperative pain: evidence and controversies  
Numerous studies have investigated sex differences in  nociception (Greenspan et 
al., 2007; Hendrich et al., 2012) and endogenous opioid pain modulation (Tambeli et al., 
2001; Fillingim and Gear, 2004; Fillingim et al., 2009). As described previously (Banik et 
al., 2006), we found that male and female mice presented similar mechanical thresholds 
and responded to plantar incision with a mechanical hyperalgesia of similar intensity and 
time course. However, these results are in contrast with other preclinical studies that 
indicate that females present lower mechanical nociceptive thresholds (Barrett et al., 
2002a; Rasakham and Liu-Chen, 2011; Hendrich et al., 2012; Chartoff and Mavrikaki, 
2015) and take longer to recover from injury than males (Vacca et al., 2014). Furthermore, 
women commonly report more severe pain than men (Greenspan et al., 2007; Tsang et al., 
2008; Fillingim et al., 2009) and are more predisposed to develop persistent postoperative 
pain (Kehlet et al., 2006). Moreover, human laboratory indicate that females present lower 
mechanical nociceptive thresholds and take longer to recover from injury than males (Riley 
et al., 1998; Fillingim and Gear, 2004).  
3.5.5 Sex differences in KOR (but not MOR) inhibition of latent 
 postoperative pain 
Our observations indicate that intrathecal administration of either low or high doses 
of CTOP equally reinstated mechanical hypersensitivity in PIM 21d male and female mice. 
By contrast, we found that intrathecal administration of a low dose of the KOR inhibitor 
LY2456302 produced a significantly more pronounced hyperalgesia and pERK activation 
in the dorsal horn of female mice as compared to male mice. The inability to demonstrate 
this sex difference with a higher dose of LY2456302 is likely due to a floor effect 
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associated with low mechanical thresholds. Although the sex differences following low 
dose LY2456302 were of small magnitude, they were statistically significant, and thus 
support our conclusion that tonic endogenous KOR-mediated inhibition of postoperative 
pain is more pronounced in females. 
Consistent with our findings related to endogenous KOR inhibition of postoperative 
pain, clinical studies suggest a sexual dimorphism in response to exogenous 
pharmacological KOR agonists in the management of postoperative pain (Pande et al., 
1996b; Pande et al., 1996a). For example, clinical trials using mixed-action MOR/KOR 
ligands and self-reported pain scales revealed that KOR agonism yields enhanced 
postoperative analgesia in women following third molar extraction (Gear et al., 1996a; 
Gear et al., 1996b, 1999). However, the literature of sex differences in the analgesic or 
antihyperalgesic actions of pharmacological agonists with selectivity at KOR is 
inconsistent or even contradictory. On one hand, KOR agonists can exert greater 
antinoception in male rodents (Barrett et al., 2002b; Terner et al., 2003a; Terner et al., 
2003b; Sternberg et al., 2004), while others suggest that KOR agonists can exert greater 
antinociception in females (Mogil et al., 2003; Lomas et al., 2007; Robinson et al., 2016). 
Similar mixed effects have been reported in rodent models of inflammatory pain: KOR 
agonists can exert greater antihyperalgesia in males as compared to females (Rasakham 
and Liu-Chen, 2011; Auh and Ro, 2012), or greater antihyperalgesia and inhibition of 
spinal Fos expression in females as compared to males (Bereiter, 2001; Clemente et al., 
2004; Lawson et al., 2010). 
The mechanisms by which endogenous KOR modulates postoperative pain in a 
sex-dependent manner remains to be answered. Sex differences in KOR pharmacology 
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have been attributed to gonadal hormones or genetic factors (Mogil et al., 2003; Rasakham 
and Liu-Chen, 2011). Sex differences in KOR-mediated mechanical and heat 
antinociception may be mediated by estrogens (Lawson et al., 2010; Robinson et al., 2016) 
and progesterone (Sternberg et al., 2004). Estrogen levels regulate KOR gene expression 
and density (Harris and Drake, 2001; Harris et al., 2004; Kren et al., 2008; Lawson et al., 
2010). Moreover, spinal estrogen signaling regulates the expression of MOR/KOR 
heterodimers (Liu et al., 2011), of which expression is higher in proestrus females 
(Chakrabarti et al., 2010).  In contrast, other studies attribute the sex differences in KOR 
analgesia to the protective effect of androgen hormones, as testosterone negatively 
regulates KOR function (van Haaren et al., 2000; Rasakham and Liu-Chen, 2011; Macedo 
et al., 2016).  
Genetics also likely contributes to sex differences in KOR analgesia. For example, 
the XY chromosome is positively associated with the expression of the dynorphin gene 
(Chen et al., 2009) and heat threshold alterations in response to KOR agonists (Gioiosa et 
al., 2008).   In the human experimental setting, a greater response to KOR mixed-agonists 
on heat and ischemic pain was observed in a subset of redheaded and fair skinned women 
related to polymorphisms on the melanocortin-1-receptor gene (MC1R) (Mogil et al., 2003; 
Fillingim and Gear, 2004). Further studies are needed to determine the contribution of 
hormonal, neurochemical, and genetic factors to sex differences in endogenous KOR 
inhibition of latent postoperative analgesia. 
 In summary, our results indicate that surgical incision leads to long-lasting, LS of 
dorsal horn neurons that is tonically opposed by prolonged activation of MOR and KOR 
signaling in the spinal dorsal horn. We found a modest, but significant sex difference in 
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neuron-dependent KOR-mediated postoperative endogenous analgesia. Considering that 
LS represents a period of susceptibility for chronic pain, sex differences in endogenous 
opioid analgesia may shed some light on potential central mechanisms involved in the 
higher predisposition of females for persistent pain states. Indeed, failure of MOR or KOR 
signaling could lead to persistent postsurgical pain. A better understanding of sex-
dependent endogenous pain inhibition by spinal KOR is essential for the development of 
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CHAPTER 4. Kappa Opioid Receptor Targets Adenylyl Cyclase 1, PKA and Epac 
to Maintain Latent Postoperative Pain Sensitization within a State of Remission  
4.1 Abstract 
  We previously reported that endogenous kappa opioid receptor (KOR) activity 
tonically inhibits latent sensitization (LS) in a murine plantar incision model of 
postoperative pain for at least 3 weeks after surgical incision. We now report that 
intrathecal injection of the KOR selective agent, LY2456302 (CERC 501, 10µg, i.t.), 
restored hyperalgesia when administered much longer, 13 months, after surgical incision.  
We next determined whether endogenous KOR maintains latent postoperative pain by 
inhibiting cAMP-dependent pathways, with a focus on adenylyl cyclase isoform-1 (AC1) 
and its two downstream receptors, protein kinase A (PKA) and exchange protein activated 
by cAMP (Epac). We used AC1 knock-out (KO) mice and pharmacological inhibitors of 
AC1 (NB001, 1.5µg i.t.), PKA (H89, 10nmol) and Epac1/2 (ESI-09, 10µg i.t.), and 
measured mechanical stimulus-evoked behaviors and immunoreactivity of phosphorylated 
extracellular signal-regulated kinase (pERK), a marker of LS-associated sensitization of 
spinal dorsal horn neurons. Postoperative hyperalgesia was attenuated in AC1 KO male 
mice. Moreover, AC1 gene deletion and NB001 precluded LY2456302-evoked 
reinstatement of hyperalgesia in both male and female mice. Furthermore, H89 prevented 
LY2456302-evoked reinstatement of mechanical hyperalgesia in male but not female mice, 
while ESI-09 reversed hyperalgesia in both sexes.  We conclude that sustained KOR 





 Persistent postoperative pain develops in millions of patients that undergo a variety 
of surgical procedures (Kehlet et al., 2006). Opioids remain the mainstay analgesics of 
acute postoperative pain; however, prolonged opioid therapy may lead to life-threating 
adverse effects, tolerance, dependence, addiction liability, and paradoxical pain 
exacerbation. A better understanding of the cellular mechanisms that drive persistent pain 
states, and opposing endogenous analgesia provided by opioid receptor signaling, may lead 
to the development of novel treatments for chronic postoperative pain. To this end, we 
employed a murine model of chronic postoperative pain that involves plantar incision of 
the hindpaw, followed by a waiting period of multiple weeks. Although hyperalgesia has 
resolved, what remains is a silent, long-lasting sensitization of nociceptive neurons in the 
dorsal horn (Solway et al., 2011; Taylor and Corder, 2014). This “latent sensitization (LS)” 
is masked by compensatory activity of multiple pain-inhibitory G-protein coupled 
receptors including μ-opioid receptor constitutive activity (MORCA (Corder et al., 2013), 
the kappa opioid receptor (KOR) [Custodio et al, submitted], and the neuropeptide Y 
(NPY) Y1 receptor (Fu et al., 2019). We previously reported that MORCA and Y1R 
suppress an LS that is driven by an NMDA receptor adenylyl cyclase-1 (AC1) 
signaling mechanism after chronic inflammation (Corder et al., 2013; Fu et al., 2019). 
For several reasons, we hypothesized that AC1 may also mediate the LS that is 
masked by KOR. First, KOR is an inhibitory G- protein-coupled receptor (GPCR), and as 
such inhibits the activity of the adenylyl cyclases (AC) (Childers et al., 1992).  Adenylyl 
cyclase 1 (AC1) is a Ca+2 - activated protein that acts as a key modulator for the induction 
of pathological pain in the CNS (Wu et al., 1995; Liauw et al., 2005; Wei et al., 2006; 
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Zhuo, 2012). It couples the intracellular Ca+2 derived from NMDAR activation to 
downstream activation of an array of downstream proteins and kinases (Zhuo, 2012). 
Similar to MOR, persistent activation of KOR by an exogenous drug can also lead to an 
AC “overshoot” (Avidor-Reiss et al., 1997; Nakagawa et al., 1999).  
AC1 – cAMP signaling activates multiple downstream targets, including the 
canonical protein kinase A (PKA) and an alternative pathway via Epac protein family 
(Cheng et al., 2008).  Epacs (Epac, isoform 1 and Epac, isoform 2) act as guanine 
nucleotide exchange factors for small GTPases (de Rooij et al., 1998; Bos, 2003), 
activating downstream PKC dependent pathways (Griffin, 2005; Hucho et al., 2005). Both 
PKA and Epac isoforms have been implicated in the development of persistent 
hyperalgesia after inflammation or tissue injury (Wang et al., 2013; Gu et al., 2016; 
Singhmar et al., 2016; Matsuda et al., 2017; Singhmar et al., 2018). 
The current studies were designed to test the hypothesis that surgical incision 
establishes a long-lasting activation of KOR signaling that masks LS, in part through tonic 
inhibition of pronociceptive AC1 signaling to downstream cAMP target proteins: protein 
kinase A (PKA) and/or exchange protein activated by cAMP (Epac). To address this 
hypothesis, we performed plantar incision in male and female mice, waited for behavioral 
signs of hyperalgesia to resolve (21 days), and targeted spinal KOR, AC1, and cAMP 
receptors with the intrathecal delivery of pharmacological antagonists (and in the case of 
AC1, we also used AC1-/- mice), and then evaluated behavioral signs of hyperalgesia and 
spinal nociceptive sensitization. The latter was assessed by the immunohistochemical 
expression of the phosphorylated extracellular-signaling kinase (pERK) in the dorsal horn.  
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4.3 Materials and Methods 
4.3.1 Animals  
Male and female mice, 8-12 week of age were obtained from commercial sources 
(C57Bl/6, Charles Rivers Laboratories) or bred in-house (adcy1-/- = AC1 knockout and 
wild-type littermate AC1+/+ controls, originally provided as a gift from Dan Storm, 
University of Washington). Genotype was confirmed by tail-snip PCR before the beginning 
of the studies. Animals were housed in a temperature-controlled room on a 14:10-hr 
light/dark cycle and were provided food and water ad libitum. All animal use protocols 
were approved by the IACUC at the University of Kentucky.  All procedures were 
approved by the Institutional Animal Care and Use Committee at the University of 
Kentucky protocol (#2017-2768), in accordance with American Veterinary Medical 
Association guidelines. Efforts were made to reduce the number of animals and their 
suffering. Mice were acclimated to the colony housing room for at least 4 days, and then 
handled for 4 days for 5 minutes prior to the initiation of the experiments.  
4.3.2 Plantar Incision Model of Postoperative Pain (PIM) 
Post-operative pain was induced by longitudinal incision of the plantaris muscle, as 
previously described (Pogatzki and Raja, 2003; Jang et al., 2011). Under isoflurane 
anesthesia (5% induction and 1.5-2% maintenance, via a nose cone) and antisepsis of the 
left hind paw with Chlorascrub® then alcohol, a #11 scalpel blade was used to perform a 
5mm through the skin and fascia using, beginning 2mm from the proximal edge of the heel 
extending towards the digits. The underlying muscle was raised with a curved forceps, 
extended 4 mm and incised longitudinally, leaving the origin and insertion of the muscle 
intact. The overlying skin was closed with synthetic 5-0 sutures (PDS*II, Ethicon), 
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followed by application of antibiotic ointment was applied. Surgery was typically 
completed within 5-10min. Sutures were removed on the post-operative day 10.  Sham 
controls received anesthesia but no surgical incision.   
4.3.3 Direct Intrathecal (i.t.) Drug Delivery 
As previously described (Fairbanks, 2003), non-anaesthetized mice were lightly 
restrained in a towel, and a 30G x1/2 needle (Becton Dickinson) attached to a 25-ul 
Hamilton micro syringe, was inserted into the subarachnoid space between the L5/L6 
vertebrae. The needle was angled about 30-45 degrees with the horizontal plane and 
slightly advanced until reflexive tail flick was confirmed, then 5 µl of drug or vehicle was 
slowly administered. The needle was held in place for 30sec, to ensure the solution fully 
enters the spinal canal, withdrawn, and then the mouse was returned to its testing chamber. 
4.3.4 Drug Dosing 
We administered 5ul of the following drugs via intrathecal route at 21 postoperative 
day mice: the compound LY2456302 (gift from NIDA Drug Supply Program) 10μg 
(Rorick-Kehn et al., 2014a; Rorick-Kehn et al., 2014b) was dissolved in ddH20 and 
sonicated at 30°C for 30minutes until complete homogenization of the drug was achieved. 
LY2456302 (Med Chem Express) 10μg was dissolved in 1:1:8 (EtOH / Chremophor 
(Sigma-Aldrich) / Saline) and injected at a dose of 10μg. Other drugs dissolved in saline 
were NB001 1.5μg (Tocris); 6Bnz-cAMP 10nmol (BioLog); H89 10nmol (Tocris); 8-CPT 
3nmol (BioLog). ESI-09 10μg (Almahariq et al., 2013; Chen et al., 2013) (gift from Jia 
Zhuo, University of Texas Medical Branch) was dissolved in 1:1:8 (EtOH / Chremophor / 
Saline). Dose-response studies previously performed in our laboratory informed our dose 
of LY2456302 (Custodio et al, submitted), NB001 were determined based on (Corder et 
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al., 2013), 6Bnz-cAMP, H89, 8-CPT, and ESI-09 (Fu et al., 2019). Control animals for the 
behavioral assays received 5μl (i.t.) of the vehicle (sterile saline or 1:1:8 (EtOH / 
Chremophor / Saline). All compounds were injected i.t. at least 3 weeks post-operatively, 
after mechanical thresholds had returned to baseline levels. Some animals from figures 
4.1A and 4.1C, 4.2A-D, 4.5A-D, and 4.7A-D were tested in a cross-over design receiving 
saline or drug a week after the first inthratecal injection. Animals were matched to 
experimental groups by a different investigator. 
4.3.5 Mechanical Hyperalgesia Testing  
All animals were acclimated in a temperature and light controlled room within 
individual Plexiglas boxes placed on the top of a stainless-steel mesh platform for 30 to 60 
min before behavioral testing. Mechanical hypersensitivity thresholds were assessed using 
an incremental series of 8 von Frey filaments (Stoelting, Illinois) of logarithmic stiffness 
(approximately 0.008-6 grams). The 50% withdrawal threshold was determined using an 
up-down method (Chaplan et al., 1994). Each filament was applied perpendicular to the 
surface of the skin just lateral to the incision site with enough force to cause a slight bending 
of the filament. A positive response was defined by a rapid withdrawal of the paw within 
5 seconds. Using the up-down method (Chaplan et al., 1994), the gram forces were 
logarithmically converted into 50% of mechanical thresholds. This test was performed by 
an observer blind to treatment at baseline up to 21 days post-PIM to confirm the 
development of mechanical allodynia and assess the reinstatement of hyperalgesia three 
weeks after surgery. Animals were assigned to experimental groups in all studies by a 
different investigator than the examiner that remained blinded until the end of all 
experiments.   
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4.3.6 Phosphorylated Extracellular Signal-Regulated Kinase (pERK) 
Stimulation 
At 21 days after surgery mice received either vehicle or LY2456302 (10µg). Two 
hours after injection, mice were lightly anesthetized with isoflurane (1.5%), and the ventral 
surface of the ipsilateral hindpaw was mechanically stimulated with gentle 2-second stroke 
with a cotton swab from heel to toe. This was repeated every 5s for 5min. After an 
additional 5 min pause, mice were deeply anesthetized with isoflurane and transcardially 
perfused with cold 0.01M phosphate buffer saline (PBS, Fischer Scientific) /heparin buffer 
(10,000 USP units/L), followed by 10% phosphate formalin buffer. Lumbar spinal cords 
were harvested and post-fixed in the same fixative overnight at 4oC, and then cryoprotected 
with 30%sucrose until total submersion (1-3 days).  
4.3.7 Histology and Immunohistochemistry 
Transverse sections (30μm) from L4 were obtained on a sliding microtome (Leica, 
SM 2000R). A series of non-consecutive sections was washed in 0.01M PBS, blocked in 
3% normal serum (goat or donkey; Gemini Bioproducts), containing 0.3% Triton X-100 
(Sigma Aldrich) in 0.01M PBS for 1h, and then incubated with primary rabbit antibody 
anti-phosphorylated-ERK ½ antiserum (1:800, Cell Signaling) at 4oC for 36 hours on a 
shaker. Sections were washed in 0.01M PBS and incubated with secondary goat anti-rabbit 
Alexa Fluor 568 conjugated antibody (1:1000, Invitrogen) for 1h. The sections were 
washed in 0.01M phosphate buffer, mounted and cover slipped with mounting medium 
with DAPI (Vectashield, Vector laboratory). 
Five good quality sections from spinal cord segments L4 per animal, in part were 
randomly selected from each subject for pERK analyses. The number of pERK-positive 
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cells on Rexed laminae I and II, and III-V were counted by a blinded examiner. All images 
were captured with a Nikon TE-2000 microscope equipped with NIS-Elements AR 4.13.05 
(Nikon), and the analyses performed with NIS-Elements Software AR analysis 4.13.05 
Software offline (Nikon). 
4.3.8 Statistical Analysis 
Data was entered into Prism software (version 8.0, GraphPad, La Jolla, CA). All 
data are presented as mean values with the corresponding standard error (mean ± SEM).  
Two-way ANOVA repeated measures (RM) was generated to analyze differences in means 
among groups over time. Drugs and doses were group factors and time was a repeated 
measure. If a significant interaction was found, ANOVA was followed by Bonferroni post-
hoc analyses. Three-way ANOVA repeated measures was used to determine effects of sex 
and treatment overtime as appropriate.  Area under the curve (AUC) or integrated 
thresholds was plotted using the trapezoidal method and analyzed using ordinary two-way 
ANOVA followed by Bonferroni. Statistical significance was set at p<0.05 (Tables 4.1 to 
4.3).  
4.3.9 Experimental blinding procedures 
All the behavioral and immunofluorescence assays were conducted by the same 
investigator (Lilian Custodio) who was blinded to the experimental groups and drugs 
during all experiments.  All the drugs and vehicles were prepared and disposed into 
identical tubes and volume. The animals were allocated to the experimental groups by a 
different examiner (Diogo dos Santos, Renee Donahue or Liping Zhang) who performed 
the tube coding using a letter system. For the Epac and PKA studies due to the different 
appearance (color) of the drugs and vehicles used that prevents an entirely blind procedure, 
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the animals were allocated in the experimental groups and injected by a different examiner 
(Diogo dos Santos or Renee Donahue after being acclimated to the animals). After the 
completion of the experiment and data plotting in an excel sheet, the code was handled to 
the examiner and the data analyzed. For the pERK experiments, to ensure blinding, the 
animals were randomly handled to the experimenter by a colleague for injections and paw 

















Table 4.1 Statistics for Figures 4.1 and 4.2.  








Drug: F1,10 = 23.23, p=0.0007 
Time: F4.87,48.72 = 22.13, p=0.001 




Drug: F1,13 = 22.60, p=0.0004 
Time: F11,143 = 23.38, p<0.0001 




Drug: F1,13 = 6.41, p=0.02  
Time: F11,143 = 31.69 p<0.0001 





Genotype: F1,33 = 8.15, p=0.007                 
Time: F3.31,109.4 = 178.2, p<0.0001       




Genotype: F1,16 = 4.77, p=0.04                   
Time: F3.29,52.77 = 93.56, p<0.0001 




Genotype: F1,15 = 3.24, p=0.09 
Time: F2.56, 38. 51 = 81.56, p<0.0001 






Table 4.2 Statistics for Figures 4.2 to 4.8 




Males and Females Males Females 
Figure 
2A 
Group:   
































































Table 4.2 Statistics for Figures 4.2 to 4.8 (continued). 
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Group:     
F3,20 = 7.29 
p=0.001 
Time:  












Table 4.2 Statistics for Figures 4.2 to 4.8 (continued). 
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F6, 54=    












Time:    

































Group:     
F3,20 = 2.13 
p=0.12 
Time:  













Table 4.3 Area under the curve (AUC) analyses 





(males and females) 
Sex: F1,48 = 0.01, p=0.89 
Drug: F3,48 = 26.34, p<0.0001 
Sex x Drug: F3,48 = 0.29, p=0.82 
Figure 4.3B 
(males and females) 
Sex: F1,12 = 1.06, p=0.32 
Drug: F1,12 = 16.59, p<0.0001 
Sex x Drug: F3,48 = 0.05, p=0.82 
Figure 4.5D 
(males and females) 
Sex: F1,33 = 5.30, p=0.02 
Drug: F1,33 = 9.29, p=0.004 
Sex x Drug: F1, 33 = 2.59, p=0.11 
Figure 4.6D 
(males and females) 
Sex: F3,40 = 1.14, p=0.29 
Group (Drug): F1,40 = 15.62, p<0.0001 
Sex x Group: F3,40 = 0.95, p=0.42 
Figure 4.7D 
(males and females) 
Sex: F1,20 = 2.13, p=0.15 
Drug: F1,20 = 25.31, p<0.0001 
Sex x Drug: F1,20 = 0.28, p=0.59 
Figure 4.8D 
(males and females) 
 
Sex: F1,40 = 1.58, p=0.21 
Group: F1,40 = 8.78, p=0.0001 












(males and females) 
Lam I-V 
Genotype: F1,28 = 16.46, p=0.0004 
Region: F1,28 = 35.35, p<0.0001 
Genotype vs Region: F1,28 = 14.35, p=0.0007 
Figure 4.4J 
(males and females) 
Lam I-II, III-V 
Genotype: F1,56 = 25.23, p<0.0001 
Region: F3,56 = 37.86, p<0.0001 
Genotype vs Region: F3,56 = 11.10, p<0.0001 
Figure 4.4K 
(males vs. females) 
Lam I-V 
Genotype: F1,12 = 16.33, p=0.001 
Group (Sex vs region): F1,12 = 0.48, p=0.50 
Genotype vs Group: F1, 12 = 0. 75, p=0.40 
Figure 4.4L 
(males and females) 
Lam I-II, III-V 
Region: F1,24 = 26.11, p<0.0001 
Group (Sex vs genotype): F3,24 = 7.26, p=0.001 











Table 4.4 Three-way ANOVA analyses  
Measure RM Three-way ANOVA  









Drug: F1,33 = 4.42, p=0.04 
Time: F2.563, 84.59= 19.17, p<0.0001 
Sex: F1,33 = 4.47, p=0.04 
Drug vs Time: F3,99 = 4.53, p=0.005  
Drug vs Sex: F1,33 = 2.01, p=0.16 
Time vs Sex: F5,165 = 1.36, p=0.24 






Drug: F1,20 = 7.84, p=0.01 
Time: F2.65,52.99 = 29.82, p<0.0001 
Sex: F1,20 = 1.80, p=0.19 
Drug vs Time: F3,60 = 10.81, p<0.0001  
Drug vs Sex: F1,20 = 0.16, p=0.69 
Time vs Sex: F3,60 = 0.41, p=0.74 








4.4 Rationale and Results 
4.4.1 Kappa-opioid receptors signal inhibit LS for at least 1 year after surgery 
Our laboratory demonstrated that repeated intrathecal (i.t.) and systemic delivery 
of the inverse agonist / non-selective opioid receptor antagonist, naltrexone, reinstated 
hyperalgesia when administered a few months after intraplantar complete Freund’s 
adjuvant (CFA) administration (Corder et al., 2013). Ongoing studies also indicates that 
naltrexone reinstates mechanical hypersensitivity up to 1 year after plantar incision (dos 
Santos, unpublished observations).  As discussed at Chapter 3, mechanical hypersensitivity 
persists up to 14 to 21 days after surgical incision of the hindpaw. We demonstrated that 
MOR and KOR are the opioid receptor systems involved in the masking of LS. To 
determine whether tonic KOR signaling also persists for such a long time beyond tissue 
healing, we performed the plantar incision model (PIM), waited for the resolution of 
mechanical hypersensitivity, and then intrathecally administered a KOR selective 
antagonist (LY2456302) 21 days, 6 months and 13 months after surgery.  
As illustrated in Figure 4.1, we found that LY2456302, but not vehicle, reinstated 
mechanical hyperalgesia when administered at either 21 days F (11, 110) = 9.40, 
p=0.0001), 6 months F (11, 143) = 5.72, p<0.0001) or 13 months F (11, 143) = 3.54, 
p=0.0002, Table 4.1) after surgery. Our findings indicate that LS and opposing KOR 






Figure 4.1. Endogenous kappa opioid inhibition of LS persists at least 13 months after 
surgical incision.  
Mechanical thresholds at baseline (BL), 2 days, and (A) 21 days, (B) 6 months, (C) up to 
13 months after plantar incision in male C57Bl/6 mice. Intrathecal administration of 
selective KOR antagonist LY2456302 (10µg), reinstated mechanical hypersensitivity 
when given (A) 21 days, (B) 6 months, (C) up to 13 months after PIM (n=6-8). BL = 
baseline behavior prior to drug administration. Data represented as mean +/- SEM.                















4.4.2 Prolonged kappa opioid receptor signaling silences behavioral and 
neuronal signs of postoperative LS via inhibition of adenylyl cyclase, isoform 
1 (AC1) 
We investigated whether prolonged KOR signaling opposes LS via inhibition of 
AC1. To answer this question, we used two approaches, an AC1 inhibitor, and AC1-/- 
mutant mice. Genetic and pharmacological interruption of AC1 does not change transient 
nociception in uninjured animals (Wei et al., 2002), but prevents CFA-induced 
hyperalgesia (Wei et al., 2002; Wang et al., 2011; Corder et al., 2013), and latent 
sensitization (Corder et al., 2013; Fu et al., 2019). To test the hypothesis that KOR inhibits 
AC1 to maintain latent postoperative pain sensitization in remission, we evaluated 
LY2456302 (10µg)-induced reinstatement of hyperalgesia in AC1 knock out mice and 
after inthratecal (i.t.) administration of the AC1 inhibitor, tested 21 days after plantar 
incision.  
As illustrated in Figure 4.2, AC1 KO mice and their wild-type controls exhibited 
similar baseline mechanical thresholds, regardless of sex. After incision, the time course 
of hyperalgesia differs across strain and sex. In males, post-incisional hyperalgesia in AC1 
knockouts resolved faster than wild-type mice (F (5, 165) = 3.29; p=0.007, Table 4.1, 
Figure 4.2A). However, when stratified by sex, AC1 KO accelerates the recovery of 
hyperalgesia in male (F (5, 80) = 3.69; p=0.004, Table 4.1, Figure 4.2B), but not female 
mice (F (5, 75) = 0.83; p=0.52, Table 4.1, Figure 4.2C). Moreover, AC1 gene deletion 
abolished reinstatement of hyperalgesia induced by KOR antagonist in wild-type animals 
(F (27, 468) = 6.25; p<0.0001, Figure 4.2A) of either sex (F (27, 216) = 4.15; p<0.0001 for 
males, fig. 4.2B; F (27, 216) = 3.12; p<0.0001 for females, Table 4.2, Figure 4.2C). 
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Integrated analyses over the 1-48h timepoints further illustrates that LY2456302-induced 
reinstatement of hyperalgesia is different between the strains (drug vs genotype, F (3, 48) 




















Figure 4.2. AC-1 gene deletion precludes KOR antagonist-induced postoperative 
hyperalgesia. 
(A-C) Mechanical thresholds at baseline (BL), 1, 4, 7, and 21 days after plantar incision in 
C57Bl/6 and AC1 KO. Gene deletion of AC1 accelerates the recovery of mechanical 
thresholds after surgery in male (B), but not female mice (C). AC1 gene deletion prevented 
LY2456302 (10µg, i.t.) – induced hyperalgesia in both male and female mice (A - D). The 
area under the curve (AUC, 1-48h) further illustrates the effect of AC1 gene deletion on 
LY2456302- (10 µg) induced reinstatement of mechanical hypersensitivity in the 
ipsilateral hindpaw (D). (n = 6-15 per group)   p < 0.05 WT compared to AC1-/- mutant. 
 p < 0.05 LY2456302 compared to vehicle. # p < 0.05 WT LY2456302 compared to AC1 
LY2456302.  p<0.05 WT LY compared to WT vehicle, AC1 vehicle and AC1 
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LY2456302. Bonferroni’s post-hoc tests followed repeated measures of 2-way ANOVA. 



















Next, we used a selective inhibitor of AC1, NB001 (1.5µg, i.t.) (Wang et al., 2011; 
Corder et al., 2013). We performed plantar incision and assessed mechanical 
hypersensitivity two days later. In 21d post-incisional mice (PIM) mice, we pre-
administered NB001 15 minutes before LY2456302 (10µg, i.t.). Consistent with our 
previous studies, spinal delivery of LY2456302 elicited reinstatement of mechanical 
hypersensitivity at 2h and 3h time points (p=0.003 and p=0.001 respectively, Figure 4.3A). 
In agreement with the AC1 KO study, NB001 abolished the reinstatement precipitated by 
LY2456302 (F (15, 135) = 4.00; p<0.0001, Figure 4.3A). This further illustrated by 
integrated analysis over 1-2h timepoints after the drug administration (drug effect, F (1, 6) 
= 21.89; p = 0.003, Table 4.3, Figure 4.3B).  
To test the hypothesis that AC1 contributes to latent sensitization of dorsal horn 
neurons, we evaluated the effect of AC1 deletion on a measure of neuronal activation in 
the dorsal horn, phosphorylated extracellular signal-regulated kinase (pERK). We 
administered LY2456302 (10 µg) intrathecally, and 2h later, at the peak of hyperalgesia, 
we performed light touch stimulation in the hindpaw of WT and AC1-/- mice.  We found 
that the number of stimulus-evoked pERK+ profiles was significantly reduced in AC1 KO 
as compared to WT mice in the ipsilateral dorsal horn (laminae I-V) (F (1, 28) = 14.35, 
p=0.0007, Figure 4.4I) in both superficial (laminae I-II) and deep dorsal horn (laminae III-
V) (F (1, 56) = 11.10, p<0.0001, Figure 4.4J). As illustrated in Figure 4.4K – L, AC1 
deletion decrease of nociceptive activation occurs in the ipsilateral dorsal horn laminae I-
V of females (F (1, 12) = 16.33, p<0.0001, fig. 4.4.K) and superficial dorsal horn of either 
sex (effect of group F (3, 24) = 7.26, p=0.01, Table 4.3, Figure 4.4.L).  
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Figure 4.3. Pharmacological inhibition of AC1 prevented LY2456302-induced 
reinstatement of postoperative hyperalgesia. 
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male 
C57Bl/6 mice. (A) Pre-administration of the AC1 inhibitor NB001 (1.5µg, i.t.) prevented 
LY2456302 (10µg) – induced reinstatement of hyperalgesia in both male and female mice. 
(B) The area under the curve (AUC) further illustrates that LY induced reinstatement in
both sexes (n= 3-8 per group).  p < 0.05 LY compared to vehicle. # p < 0.05 NB001 + 
LY2456302 compared to Vehicle + LY2456302. BL = baseline behavior prior to drug 
administration. Bonferroni’s post-hoc tests following repeated measures of 2-way 
ANOVA. Data represented as mean +/- SEM.  
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Figure 4.4. AC1 gene deletion prevented LY2456302 - induced reinstatement of 
neuronal activity in the dorsal horn. 
Representative images of pERK immunoreactivity in the dorsal horn of female (A-D), and 
male (E-H) mice. (A, E) LY2456302 (10 µg, i.t.) enhanced the number of pERK+ cell 
profiles in WT mice in the ipsilateral side (A, E) as compared to the contralateral side (B, 
F). In contrast to WT, few pERK-positive cells were observed in AC1-/- mice ipsilateral 
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paw (C, G) compared to contralateral (D, H). (I - J) Histograms illustrate that LY2456302 
i.t. administration increased the number of pERK+ cells in WT compared to AC1-/- male
and female mice. Images were taken with a 10X objective. n = 8 per group/4 per sex. Data 
represent mean +/- SEM. ★ p<0.05. Bonferroni’s post-hoc tests following 2-way ANOVA. 
Scale bars: 100μm. 
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4.4.3 PKA activation reinstates behavioral signs of postoperative hyperalgesia 
in male but not female mice  
Recent evidence from our laboratory suggests that the cAMP receptors, PKA and 
Epac1 and Epac2, are activated after nerve injury and intraplantar CFA in male rodents (Fu 
et al., 2019). Our findings indicate that LS is driven by pronociceptive AC1 signaling in 
the dorsal horn in both male and female mice. Therefore, we hypothesized that AC1 
signaling recruits both PKA and Epac downstream signaling.  
We recently reported that intrathecal administration of the selective cAMP analog 
6-bnz-cAMP (6-bnz, 10nmol) reinstated mechanical when tested in male mice that
received intraplantar CFA 21 days earlier (Fu et al., 2019), but this study was restricted to 
male mice. As illustrated in Figure 4.5A, 6-bnz reinstated hyperalgesia in 21d PIM mice 
(F (6,156) =3.93, p=0.001). The 3-way ANOVA analyses revealed significant effects of 
sex, drug and time (p=0.04, p=0.04 and p<0.0001 respectively, Table 4.4). When the data 
were stratified by sex, we found that 6-bnz reinstated mechanical hypersensitivity 21d PIM 
male mice (RM Two-way ANOVA, drug effect F (2, 24) =8.84, p=0.01 and drug and time 
interaction F (6, 72) =3.58, p=0.003, Table 4.2, Figure 4.5B), and showed no effect in 
female mice (RM Two-way ANOVA, drug effect F (2, 25) =0.58, p=0.56 and drug and 
time interaction F (6, 75) =1.03, p=0.041, Table 4.2, Figure 4.5C). As illustrated in Figure 
4.5D integrated analysis over time revealed the effects of sex (F (1, 33) = 5.30, p=0.02) 
and drug (F (1, 33) =9.29, p=0.004, Table 4.3) on 6-bnz induced-reinstatement of 
mechanical hypersensitivity (p=0.01 and p>0.99 for males and females respectively).  
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Figure 4.5. PKA activation reinstates behavioral signs of postoperative hyperalgesia 
in male but not female mice. 
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male 
and female C57Bl/6 mice. Intrathecal administration of (A) PKA activator, 6-bnz 
(10nmol), reinstated mechanical hyperalgesia in 21day post-operative but not sham mice. 
Reinstatement was elicited in (B) male, but remarkably not (C) female mice. n = 9-18. (D) 
The area under the curve (AUC, 0.5-1h) further illustrates the effect of sex on 6-bnz 
(10nmol) driven mechanical hypersensitivity in the ipsilateral hindpaw. ★p < 0.05 6-bnz 
vs. vehicle or sham. Data represented as mean +/- SEM. Bonferroni’s post-hoc tests 
following ordinary or repeated measures of 2-way ANOVA.  
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Next, we tested the hypothesis that PKA is necessary for the LS that is masked by 
KOR. To answer this question, we pre-administered H-89 (10nmol, i.t.), a selective 
inhibitor of PKA, 15 min prior to LY2456302 (10µg) delivery. Figure 4.6 illustrates that 
PKA inhibition by H89 prevented LY2456302-induced hyperalgesia (drug vs. time 
interaction, F (18,264) = 6.73, p<0.001, Table 4.2, Figure 4.6A) in 21PIM mice. 
Corroborating with our previous data, H-89, but not the vehicle, prevented LY2456302-
induced reinstatement of hyperalgesia exclusively in male mice (drug vs. time interaction; 
F (18,120) = 2.76, p=0.001, Table 4.2, Figure 4.6B), which is further illustrated by the 
AUC (1-3h) analysis (drug vs. time interaction, F (18, 120) = 4.99, p<0.0001 for males and 
p=0.69 for females Bonferroni multiple comparisons, Table 4.3, Figure 4.6D). Together 
these results suggest that PKA contributes to postoperative LS in males, but not females.  
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Figure 4.6. PKA inhibition prevents the reinstatement of KOR antagonist-induced 
postoperative hyperalgesia in male mice.   
(A) Pre-administration of H89 (10nmol) prevented LY2456302 (LY, 10µg)-induced
reinstatement of mechanical hypersensitivity in 21-day postoperative mice. However, 
when the results were stratified by sex, PKA inhibition reversed LY2456302 -induce 
reinstatement (B) only in male, (C) but not female mice. (D) The area under the curve 
(AUC) further illustrates that LY2456302 induced reinstatement in both sexes, but H89 
prevented LY2456302 reinstatement only in male mice. n= 6-12. ★ p < 0.05 vehicle + 
LY2456302 vs. vehicle + vehicle. # p<0.05 H89 + LY2456302 vs. vehicle + LY2456302. 
∆ p<0.05 VHC + LY2456302 vs. H89 + VHC.  Data represented as mean +/- SEM. 
Bonferroni’s post-hoc tests followed repeated measures 2-way ANOVA.  
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4.4.4 Epacs activation reinstates behavioral signs of postoperative 
hyperalgesia in male and female mice 
Cumulative evidence indicates that Epacs are required for the development of 
persistent hyperalgesia after inflammation or tissue injury (Wang et al., 2013; Gu et al., 
2016; Singhmar et al., 2016; Matsuda et al., 2017; Singhmar et al., 2018) and LS (Fu et al., 
2019) . Thus, we proposed that Epacs signaling drives LS that is masked by spinal KOR 
activity. To test whether Epacs mediates the pronociceptive effects of LS, we i.t. 
administered the Epac selective activator 8-CPT at a dose (3nmol) previously determined 
in our laboratory (Fu et al., 2019). Figure 4.7A illustrates that 8-CPT precipitated 
mechanical hyperalgesia in both male and female 21 d PIM mice (drug vs time interaction, 
F (6, 99) =5.27, p<0.0001, Table 4.2). Three-way ANOVA revealed significant effects of 
8-CPT (p=0.01, Table 4.4) in 21d PIM mice. Subsequent two-way ANOVA analyses 
shown 8-CPT effects in both sexes (drug vs time interaction, F (6, 54) =3.01, p=0.01, F (6, 
45) =3.60, p=0.005, for males and females respectively), but not sham controls (Figures 
4.7.B-C). As illustrated in Figure 4.7.D AUC (0.5-1h) analysis revealed the significant 
effects of 8-CPT (F (6, 45) = 3.60, p=0.005, Table 4.3) on the reinstatement of mechanical 
hypersensitivity in male and female mice. These data demonstrated that Epac signaling 
promotes persistent postoperative latent hyperalgesia in rodents that is under inhibitory 








Figure 4.7. Epacs drives postoperative latent sensitization in male and female mice  
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male 
and female C57Bl/6 mice. We used the EPAC activator, 8-CPT, to determine whether 
surgical incision sensitizes EPAC signaling. (A) Intrathecal administration of 8-CPT 
(3nmol) reinstated mechanical hypersensitivity three weeks after surgical incision in (B) 
male and (C) female mice. (D) The area under the curve (AUC, 0.5-1h) further illustrates 
the effects of sex on (8-CPT 3nmol) on mechanical hypersensitivity in the ipsilateral 
hindpaw. n = 6-12 per group. Data represent mean +/- SEM. ★ p < 0.05 8-CPT vs. vehicle 
or sham. Data represented as mean +/- SEM. Bonferroni’s post-hoc tests following 
ordinary or repeated measures of 2-way ANOVA. 
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4.4.5 Prolonged kappa opioid receptor signaling silences behavioral signs of 
postoperative LS via Epacs in male and female mice 
Lastly, we investigated whether KOR-masked LS is driven by the AC1 downstream 
proteins Epac1-2. We performed behavior pharmacological experiments using a non-
selective Epac inhibitor ESI-09 (10µg) (Almahariq et al., 2013) delivered intrathecally 
15min prior to LY456302 (10µg) i.t. administration in 21d PIM mice. We found that ESI-
09 administration prevented the mechanical hyperalgesia induced by LY2456302 (drug vs. 
time interaction, F (18, 264) =5.13, p<0.001, Figure 4.8A) in both male (drug vs. time 
interaction, F (18, 120) =3.99, p=0.0005, Figure 4.8B) and female mice (drug vs. time 
interaction, F (18, 120) =2.21, p=0.05, Figure 4.8C). The effects of ESI-09 on 
LY2456302-induced reinstatement of hyperalgesia are further illustrated at the AUC (1-
2h) analysis (Table 4.3, Figure 4.8D). Together, our findings indicate that Epac1-2 is a 
mutual contributor to latent postoperative hyperalgesia in male and female mice. Moreover, 













Figure 4.8. Pharmacological inhibition of Epac1-2 prevents the reinstatement of KOR 
antagonist-induced postoperative hyperalgesia.                                                                                                       
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male 
and female C57Bl/6 mice. We pre-administered the non-selective EPAC inhibitor ESI-09 
before LY2456302. Intrathecal administration of ESI-09 (10µg) prevented LY2456302-
induced mechanical hyperalgesia in 21day post-operative mice (A). This was true in both 
(B) male mice, and (C) female mice. (D) The area under the curve (AUC, 1-2h) illustrates 
the effects of ESI-09 (10µm) on LY2456302-induced reinstatement of mechanical 
hypersensitivity on both sexes. n = 6-12 per group.  p< 0.05 LY2456302 compared to 
vehicle. # p < 0.05 LY2456302 + vehicle compared to ESI-09 + LY2456302 represented 




4.5.1 Latent sensitization is driven by AC1 signaling in the dorsal horn  
As a Gi/o receptor, KOR activation promotes analgesia via adenylyl cyclase 
signaling inhibition (Chen et al., 1993; Bruchas and Chavkin, 2010). Similar to MOR 
signaling, withdrawal from chronic administration of KOR agonists leads to AC1 
superactivation (Avidor-Reiss et al., 1995; Avidor-Reiss et al., 1997). AC1 is a key 
modulator of pain-related neuronal plasticity (Zhuo, 2012), as it links NMDAR activation 
to pronociceptive cAMP signaling effectors increasing susceptibility to chronic pain 
(Taylor and Corder, 2014). In addition, selective blockade of NMDAR precludes Nor-BNI 
-precipitated hyperalgesia after recovery of postsurgical pain (Campillo et al., 2011), 
indicating a role of NMDAR in postoperative LS. Thus, we hypothesized that KOR tonic 
activity silences postoperative hyperalgesia via inhibition of AC1 pronociceptive signaling, 
impeding the development of persistent postsurgical pain. 
We found that genetic deletion of AC1 attenuates the degree of postoperative 
hyperalgesia, accelerates the recovery of baseline thresholds in males and reverses 
LY2456302-induced reinstatement of mechanical hypersensitivity on postoperative day 21 
in both sexes. Similarly, pharmacological inhibition of AC1 prevents KOR-antagonist 
mediated hyperalgesia.  Moreover, spinal nociceptive transmission induced by KOR 
blockade was markedly reduced in AC1KO mice compared to WT littermates. 
Collectively, our results indicate that AC1 is necessary for the development of latent 
postsurgical hyperalgesia. These results are in agreement with previous studies that suggest 
that AC1 is required for the establishment of pain-related sensitization (Xu et al., 2008a; 
Yamanaka et al., 2017) and modulates inflammatory and persistent pain states, (Wei et al., 
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2002; Wang et al., 2011; Corder et al., 2013), including the latent inflammatory pain that 
is masked by MORCA (Corder et al., 2013). 
It is well accepted that AC1 is required for the induction of spinal LTP (Wang and 
Zhuo, 2002; Wang et al., 2011). KOR pharmacological blockade notably reduced but did 
not erase spinal nociceptive transmission assessed by pERK expression in the dorsal horn 
of AC1 mutant mice. Other AC isoforms besides AC1 may also contribute to LS. It is 
conceivable that AC1 gene deletion leads to a compensatory upregulation of different AC 
isoforms such as its calcium-calmodulin counterpart AC-8 (Wei et al., 2006). This is in 
agreement with previous studies showing that AC-8 contributes to a lesser extent to LTP 
(Xia and Storm, 1997) and the development of inflammatory pain (Wei et al., 2002). 
Despite a possible effect of AC8, our findings collectively support the notion that AC1 is 
the critical regulator of LS. Together, our data strongly suggest that AC1 is required for 
persistent nociceptive sensitization within the spinal nociceptive circuits. Therefore, we 
propose that prolonged spinal KOR activity negatively regulates AC1 pronociceptive 
pathways after surgery, which in part, keeps LS within a state of remission.  
4.5.2 Sex differences in the latent sensitization is driven by a PKA-dependent 
pathway: PKA-mediated LS in females but not males 
The canonical cAMP-PKA pathway is critically involved in the development 
(Taiwo et al., 1989; Malmberg et al., 1997; Yajima et al., 2003) and maintenance of 
hyperalgesia after inflammatory injury (Sluka, 1997; Aley and Levine, 1999; Aley et al., 
2000; Tumati et al., 2011), or prolonged opioid exposure (Tumati et al., 2011; Araldi et al., 
2015; Chen et al., 2018b). Recent data from our laboratory demonstrates that prolonged 
PKA activation also participates in the pain-related sensitization (LS) associated with 
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persistent inflammation and nerve injury (Fu et al., 2019).  However, these studies focused 
exclusively on males. Therefore, we assessed whether PKA persistent activity also 
contributes to postoperative latent sensitization masked by KOR signaling on both sexes.   
Strikingly, we found that PKA activation failed to reinstate mechanical 
hypersensitivity in female mice three weeks after paw incision. In addition, we 
demonstrated that PKA inhibition using H-89 reversed the pronociceptive effects of 
LY2456302 only in injured male, but not female mice. These results imply that there are 
important sex differences in the cellular mechanisms underlying LS. To the best of our 
knowledge, we are the first to evaluate the direct contribution of PKA signaling in 
persistent postoperative pain. Our observations, however, are in agreement with findings 
in different chronic pain models. For example, a recent study conducted in female mice 
suggests that the development of hyperalgesic priming (LS) and consolidation of chronic 
musculoskeletal pain require the activation of the PKC-ERK pathway in the spinal cord, 
but is independent of PKA signaling (Chen et al., 2018c).  
One possible mechanism for the lack of sensitivity to PKA in females after injury 
is the negative regulation of PKA by estrogen. Levine and colleagues found that in contrast 
to males, epinephrine-induced hyperalgesia in the spinal cord is independent of protein 
kinases activity in normally cycling or gonadectomized females receiving hormonal 
replacement. However, PKA signaling was restored in ovariectomized animals (Dina et al., 
2001).  Conversely, an in vitro study revealed that membrane estrogen receptors regulates 
ERK phosphorylation, but do not influence PKA activity (Nag and Mokha, 2014).  
Our findings indicate that postoperative spinal sensitization is independent of PKA 
signaling in female mice, although, these results should be interpreted with caution. First, 
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the doses used in our studies were based on dose-response curves established in 
pharmacological studies in male mice. Therefore, the pharmacokinetics of these drugs 
might differ between male and female mice. Second, although we failed to demonstrate the 
contribution of PKA in the remission phase of LS, we cannot exclude the participation of 
cAMP-PKA signaling in the induction of acute postoperative pain. Recent evidence 
indicates that PKA is required for the induction of hippocampal LTP in females, but not 
male mice (Jain et al., 2019). Similarly, PKA activity in nociceptors is required in acute 
and persistent inflammatory models in females (Aley and Levine, 1999; Araldi et al., 
2015). Thus, it is conceivable that as inflammation remits and spinal nociceptive plasticity 
persists, there is a shift from a PKA dependent to a PKA-independent mechanism 
associated with the activation of distinct signaling pathways. For example, a studies in 
female mice showed that inflammation alters G-protein-coupled receptor kinase 2 (GRK2) 
protein levels in the spinal cord and leads to cross talk of GRK2 with Epac and ERK 
signaling, independently of PKA leading to persistent hyperalgesia (Eijkelkamp et al., 
2010; Huang and Gu, 2017). Alternatively, the activation of parallel cAMP pathways may 
be sufficient to produce persistent hyperalgesia after surgery in females.  
4.5.3 Contribution of Epacs to latent postoperative pain 
 
We found that Epac activation by 8-CPT-cAMP (Rehmann et al., 2003) restores 
mechanical hypersensitivity at least 21 days after surgery in both male and female mice.  
We speculate that similar to AC1 (Corder et al., 2013), tissue injury leads to superactivation 
of Epacs. This would fit with previous observations that Epac1 and Epac2 expression are 
markedly increased 14 days after surgical incision in the DRG and dorsal horn in a subset 
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of small non-peptidergic fibers (Cao et al., 2016; Matsuda et al., 2017), although expression 
does not equal Epac activity, and Epac activity was not measured in these studies.  
We found that the Epac1-2 inhibitor ESI-09 prevented the ability of LY2456302 to 
reinstate hyperalgesia, indicating that Epac is required for the maintenance of LS. Our 
findings are in agreement with a previous study demonstrating that ESI-09 prevents 
hyperalgesia induced by the administration of inflammatory mediators 14 days after 
surgical incision, but did not affect acute postoperative pain (Matsuda et al., 2017).  The 
effects of Epac in persistent postsurgical hyperalgesia in these studies were mediated by 
p38MAPK (Matsuda et al., 2017) and lead to the translocation of PKC in primary afferents 
(Hucho et al., 2005), suggesting the contribution of PKC in LS. Moreover, the  activation 
of  specific PKC isoforms by Epac signaling was recently demonstrated in vitro (Goode 
and Molliver, 2019). However, the role of downstream effectors of Epac in LS remains to 
be determined. 
Collectively our data indicate significant sex differences in latent postoperative 
pain. We propose that an AC1-cAMP-PKA mechanism drives LS in males, while AC1-
cAMP–Epac signaling is a common mechanism underlying LS in both males and females. 
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CHAPTER 5 – Final Discussion, Conclusions, and Future Directions 
 
 
5.1 General Discussion  
In this dissertation we aimed to investigate the contribution of opioid receptor 
subtypes to postoperative latent sensitization and cellular mechanisms that drive LS in male 
and female mice.  Our findings indicate that spinal MOR and KOR, but not DOR mask LS.  
Furthermore, our data indicate that surgical incision activates AC1, PKA, and Epac pain 
facilitatory processes, which in turn, is opposed by a long-lasting spinal KOR inhibitory 
signaling. One of our main findings is that spinal KOR activity differentially regulates LS 
in male and female mice. Moreover, cAMP dependent pathways drive postoperative LS in 
a sex-dependent manner. These findings have important implications for the development 
of new therapeutics targeting postsurgical pain. 
5.1.1 Kappa opioid system: paradoxical effects in pain modulation  
 
The contribution of the KOR-dynorphin system in pain modulation has been extensively 
investigated in rodents and human subjects in the past decades.  According to the site of 
action in the pain neuroaxis, KOR agonism result in analgesia or hyperalgesia. For 
instance, peripheral restricted (Snyder et al., 2018), and KOR agonists injected into the 
RVM (Hurley and Hammond, 2000; Schepers et al., 2008a) promote analgesia after injury; 
while KOR activation in the central amygdala leads to hyperalgesia in primed animals (Xie 
et al., 2017).  
At the spinal cord level, dynorphin peptide administration leads to analgesia in 
several models of acute pain, an effect that is mediated by coupling to KOR (Spampinato 
and Candeletti, 1985; Podvin et al., 2016). In contrast, in chronic inflammatory and nerve 
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injury models dynorphin elicits hyperalgesia/allodynia via non-opioid pathways, possibly 
through direct or indirect interaction with NMDA or bradykinin receptors (Vanderah et al., 
1996; Tan-No et al., 2002; Lai et al., 2006; Luo et al., 2008). Our results demonstrated that 
blockade of spinal KOR with long- or shorter-acting selective compounds during LS 
reinstates hyperalgesia over one year after surgical incision, which is accompanied by 
increased nociceptive spinal transmission. Thus, we provided compelling evidence that 
spinal KOR signaling elicits a long-lasting postoperative endogenous antinociceptive 
effect. Therefore, it is reasonable to speculate that spinal KOR masks nociceptive 
sensitization in the dorsal horn after surgery through increased constitutive activity or 
dynorphin-independent signaling. This hypothesis was not tested in this dissertation; 
however, it is in agreement with the study of Walwyn and colleagues that showed that long-
acting KOR antagonists produce hyperalgesic effects at similar magnitude on 21-day CFA 
WT and pre-prodynorphin deficient mice (Walwyn et al., 2016). In this line of thought, 
systemic administration of the KOR antagonist Nor-BNI reinstates mechanical 
hyperalgesia in surgical incised and opioid-treated mice with no evidence of changes in 
spinal dynorphin levels (Campillo et al., 2010). Moreover, constitutive activity of KOR 
was recently demonstrated in vivo in a preclinical model of stress-induced drug relapse. 
Collectively, our results suggest that not only MORCA but also by long-lasting KOR 
signaling may preclude the transition from acute to chronic postoperative pain.  
5.1.1.1 Kappa opioid receptors as a potential therapeutic target for chronic 
pain and addiction 
The “holy grail” of opioid pharmacology is the development of opioids devoid of 
the potentially fatal, and undesirable addictive effects of MOR. KOR is an attractive target 
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since its activation does not elicit MOR-related adverse effects such as respiratory 
depression, nausea, constipation, and has lower abuse potential (Chavkin, 2011). While 
euphoria results exclusively from MOR activation in the mesocorticolimbic system, KOR 
activation in the brain generates dysphoria and psychotomimetic effects (White and Roth, 
2012). Thus, despite the robust postoperative analgesic effects of full KOR agonists 
(Pande et al., 1996a), the psychotomimetic effects in therapeutic dosages had refrained 
these drugs from further use in the clinical setting (Pfeiffer et al., 1986).  
Therefore, in the field of KOR therapeutics, efforts have been concentrated in the 
identification of new compounds that work through selective signaling pathways (bias 
agonism) independent of β-arrestin and MAPK pathways entailed to the aversive effects 
of kappa (Land et al., 2008; Chavkin, 2011).   To date, these compounds were tested 
predominantly in vitro (White et al., 2015; Schattauer et al., 2017). Future studies in vivo 
may shed some light on the analgesic efficacy of those compounds. Emerging research 
have focused on the peripheral analgesic properties of KOR as potential treatment for 
visceral pain (Stein et al., 2009; Snyder et al., 2018), however the clinical applicability of 
these drugs has been contested as at higher doses peripheral restricted agonists can still 
cross the blood brain barrier and elicit similar CNS adverse effects (Nielsen et al., 2015; 
Naser and Kuner, 2018).  
Alternatively, KOR antagonists have been proposed as potential treatment for 
nociplastic disorders triggered by stress, such as migraines (Xie et al., 2017).  As 
previously discussed, Nor-BNI and other long-lasting KOR antagonists due to its extended 
duration of action and likely cumulative effects are unsuitable for clinical use. The short-
acting drugs used at the abovementioned studies are at early stages of development and 
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have been tested so far only in preclinical studies. The results of these studies, however, 
are very preliminary, due to the paucity of translational models of chronic stress. 
Moreover, stress is only one of the initiator factors and comorbidities of these chronic pain 
conditions and are not easily identified clinically. One of the KOR antagonists used in this 
dissertation LY2456302 (currently known as CERC501) is currently in phase II clinical 
trials for major depression. Despite the uncertainty of short KOR antagonists to manage 
chronic pain, they may represent a good adjuvant or monotherapy for the treatment of 
post-traumatic stress and substance use disorders (Rogala et al., 2012; Reed et al., 2018).  
5.1.2 Postoperative latent sensitization may be silenced by synergism of the 
opioidergic and other GPCR systems 
In this dissertation, we demonstrated that LS is maintained quiescent by the long-
lasting activity of MOR and KOR after surgery. Our laboratory previously demonstrated 
that MOR increased constitutive activity (MORCA) after injury that persistently represses 
hyperalgesia (Corder et al., 2013).  However, LS is also opposed by non-opioidergic 
receptor systems. For example, blockade of NPY-Y1R reinstates mechanical and thermal 
hyperalgesia in 21-day mice that received intraplantar CFA and 28 days after nerve injury  
(Solway et al., 2011; Fu et al., 2019). Remarkably, pharmacological blockade of Y1R, 
MOR and KOR reinstates hyperalgesia in a similar magnitude. These observations raised 
the question of whether NPY and opioid systems act in concert through a synergistic or 
additive effect. Ongoing studies in our laboratory indicate endogenous synergism between 
these two receptor systems (dos Santos et al., unpublished findings), however, whether 
they are co-expressed in the same population of dorsal neurons remains to be determined. 
Functional interaction between GPCR has implications in pharmacology. For example, 
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the formation of homo and heterodimerization between GPCR has been described 
primarily in vitro, but still controversial  (Al-Hasani and Bruchas, 2011).  A recent study 
evaluated the co-expression of MOR and DOR in vivo (Wang et al., 2018). An intriguing 
hypothesis is that injury increases the formation of pain modulatory receptors systems 
heterodimers to potentiate inhibitory signals and to combat pronociceptive effects during 
LS.  
5.1.2.1 Tonic cannabinoid receptor-1 and cannabinoid receptor -2 activity 
suppresses postoperative hyperalgesia 
Endocannabinoid receptor systems are implicating in the modulation of 
postsurgical pain (Alkaitis et al., 2010). Similar to MOR and KOR, we found that CB1 
and CB2 receptors blockade reinstates mechanical hypersensitivity in a dose-dependent 
manner three weeks after surgical incision (data not shown), but in a lesser magnitude. 
We then investigate whether CB1 receptors exert their analgesic effects after surgery via 
constitutive activity. We found that the neutral antagonist AM4113 failed to reverse the 
hyperalgesic effects of the inverse agonist rimonabant in the dorsal horn. Our results 
suggest that CB1 is activated by their endogenous ligand after surgery to modulate 
postsurgical hyperalgesia. Functional interactions between CB1 and KOR has been 
described. Moreover,  activation of CB1 and MOR heterodimers markedly reduced ERK 
signaling compared to the individual activation of these receptors  (Al-Hasani and 
Bruchas, 2011). Thus, it is possible that MOR and/or KOR and CB1 act in synergism to 





Figure 5.1. Spinal administration of CB1 inverse agonist reinstates mechanical 
hypersensitivity in surgical incised mice.  
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male 
C57Bl/6 mice. The inverse agonist Rimonabant (30µg, i.t.) induced reinstatement of 
hyperalgesia (n= 6-7 per group) in male mice effect that was not abolished by the pre-
administration of the neutral antagonist AM 4113 in either 1mg/kg (i.p.) (B) or 10mg/kg 
(i.p.) dose.  p < 0.05 vehicle + Rimonabant compared to vehicle + vehicle. Bonferroni’s 
post-hoc tests following repeated measures of 2-way ANOVA. Data represented as mean 
+/- SEM.  
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5.1.3 Sex differences in Latent Sensitization 
In this dissertation, we explored the effects of spinal KOR signaling following 
surgical incision in a preclinical model of postoperative pain.   Our results demonstrated 
that KOR prolonged signaling within the spinal nociceptive system promotes 
postoperative endogenous analgesia in rodents. As previously emphasized, KOR agonists 
were previously tested for postoperative pain in the clinical setting with limited analgesic 
efficacy due to its narrow therapeutic window (Pfeiffer et al., 1986). Interestingly enough, 
selective KOR agonists and mixed-action partial agonists were more efficacious 
postoperatively in women and female rodents (Gear et al., 1996a; Gear et al., 1996b; 
Pande et al., 1996a). These findings substantiate our observations that endogenous KOR 
signaling are more pronounced in female mice after surgery. Sex differences in opioid 
analgesia is attributed to gonadal hormones regulation of spinal KOR expression and 
signaling, and genetic predisposition.  
A remarkable finding in our studies is that c-AMP dependent signaling after surgery 
differs between sexes. In females, LS is driven by a PKA independent pathway, while 
AC1-Epac is a common mechanism in both males and females. One possibility is that 
gonadal hormones negatively regulate PKA in females. Alternatively, it is conceivable 
that cAMP-PKA signaling is present in the first stages of the development of postoperative 
hyperalgesia, and as hyperalgesia progresses a shift from PKA to other pathways (i.e. 
Epac) occurs due to the influence of other kinases. Nevertheless, the investigation of 
differences in pain signaling pathways is important to determine possible mechanisms 
associated with the higher predisposition of females to develop chronic pain, and sex-
specific therapeutic targets.  
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5.1.4 AC1 and Epac are potential therapeutic strategies for the management 
of chronic postoperative pain 
Our data and previous studies in our laboratory indicate that AC1 and Epac are 
required in the transition from acute to persistent pain states in rodents. AC1 and Epac 
superactivation are common mechanisms in LS opposed by opioid and other receptor 
systems (Corder et al., 2013) (Fu W et al., in revision), and are observed in both male and 
female mice. The window of activation of these proteins after surgery, however; remains 
unclear. An interesting feature of postoperative pain is the presence of a clear etiology that 
allows the distinction between acute pain and the progression to persistent pain states, 
which is a challenge of most chronic pain conditions. AC1 is an interesting candidate as 
its inhibition not only promotes analgesia but also combats opioid dependence. Moreover, 
AC1 is highly expressed in the brain and contributes to the regulation of synaptic 
plasticity, learning, and memory. Thus, a certain degree of cognitive impairment is an 
expected adverse effect in future clinical trials. The development of drugs targeting AC1 
downstream targets, i.e., Epac protein may circumvent these limitations.  
Moreover, current studies in our laboratory conducted by Dr. Liping Zhang also 
demonstrate that systemic administration of the Epac inhibitor, ESI-09, reduces 
mechanical hypersensitivity and ongoing pain in a preclinical model of chronic 
neuropathic pain. These observations reinforce the analgesic potential of Epacs and their 
indication for the management of chronic pain. In summary, our studies indicate that 
pharmacological AC1 and Epac inhibitors silence postoperative LS. Therefore, drugs 
targeting AC1 and Epacs may represent good alternatives to manage chronic postoperative 
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pain, avoiding the prolonged use of opioids and their deleterious side effects such as 
tolerance, dependence, and addiction. 
5.2 Conclusions  
In this dissertation, we employed a preclinical model of chronic postoperative pain 
that is ideally suited to assess candidate-signaling molecules involved in the maintenance 
of pain-related plasticity and the receptor systems involved in postoperative latent pain 
sensitization (LS). We demonstrated that pharmacological blockade of KOR (or MOR) 
markedly restores mechanical hypersensitivity and spinal sensitization at least three weeks 
after surgical intervention. Furthermore, KOR antagonism reveals a silent, persistent 
sensitization mediated by AC1 and downstream cAMP-dependent signaling pathways. 
Figure 5.2 summarizes this work. 
 Our work also indicates that surgical incision promotes long-lasting MOR and 
KOR endogenous analgesia in the dorsal horn of the spinal cord that persists for at least 
one year after injury. We reasoned that long-term KOR activation represses a prolonged 
AC1 – cAMP – PKA and/or AC1- cAMP - Epac spinal pronociceptive signaling which, 
in part, maintains LS within a state of remission.   Thus, our observations suggest that any 
disruption of spinal MORCA or KOR signaling, i.e., caused by significant stressful events 
or additional injury, may potentiate LS pronociceptive signals leading to persistent 
postoperative pain. Therefore, we propose that spinal KOR activation precludes the 
transition from acute to chronic postoperative pain via inhibition of AC1 and cAMP-
dependent pathways. 
We further extended the literature assessing the influence of biological sex on LS. 
We provided evidence of a small magnitude, but significant sex difference in endogenous 
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KOR-mediated postoperative analgesia. Our data suggests that females possess enhanced 
spinal KOR signaling after tissue injury, which may explain, at least in part, the observed 
sexual dimorphism in the responsiveness to KOR agonists administered postoperatively 
in clinical trials (Gear et al., 1996a; Gear et al., 1996b; Pande et al., 1996b; Pande et al., 
1996a). Intriguingly, this work further demonstrates a sexual dimorphism in the c-AMP 
dependent pathways involved in the induction and maintenance of pain-related plasticity 
following surgical intervention, wherein male both AC1-cAMP-PKA and AC1- cAMP- 
Epac drive LS, while in females LS is driven by AC1-cAMP-Epac, i.e., a PKA-
independent mechanism. Moreover, selective AC1 and Epac inhibitors reverse the 
reinstatement of mechanical hypersensitivity induced by KOR antagonist in both male 
and female mice while PKA selective inhibition precludes LY2456302-reinstatement of 
mechanical allodynia only in male mice, confirming that both AC1-cAMP pathways are 
under the inhibitory control of KOR signaling. Our observations raise the prospect that 
differences in signaling pathways modulating spinal nociceptive plasticity may help to 
explain the higher susceptibility of females to develop chronic postoperative pain. 
We present Epac as a new potential therapeutic target to manage chronic 
postoperative pain, and AC1 inhibitors as a possible effective treatment for postoperative 
pain. As noted, AC1 inhibition accelerates the recovery from postoperative pain in males, 
and the effects of AC1 inhibition are more noticeable as hyperalgesia persists. Therefore, 
the identification of sex-specific therapeutic targets should be taken into account as new 









Figure 5.2. A conceptual model of pronociceptive signaling pathways suppressed by 
endogenous KOR long-lasting activity in the dorsal horn following surgery in male 
and female mice.  
Arrows indicate activation; Line Bottom indicates inhibition; Blue Arrow indicates future 


















5.3 Future Directions 
1. In chapter 3, our behavioral pharmacological experiments revealed that KOR signaling 
maintains LS within a state of remission after surgical incision. Both Nor-BNI and 
LY2456302 dose-dependently (in a M - M range) reinstated mechanical hypersensitivity 
at postoperative day 21.  In vitro and in vivo studies show that Nor-BNI has a slow onset 
(hours –systemically (Munro et al., 2012); 30 minutes i.c.v. (Horan et al., 1992), and 
transient MOR signaling effects during the first hours of action. A recent animal and 
clinical studies also indicated that higher doses of LY2456302 might have off-target effects 
at MOR (Reed et al., 2018). To date, the literature had evaluated the systemic effects of 
LY. For the best of our knowledge, we are the first to assess the i.t. effects of this 
compound. Thus, despite the low dosages used in our studies, future experiments using 
KOR KO mice would help to further ratify our findings. Alternatively, selective deletion 
of spinal KOR (i.e.) using dynorphin-saporin i.t. administration before plantar incision 
could also be used. Moreover, behavioral pharmacological trials testing whether 
LY2456302 or Nor BNI at 1 - 10µg dose reverts the effects of equi-antinociceptive i.t. 
doses of MOR agonists, i.e. morphine or DAMGO, after surgical incision can also help to 
confirm the selectively of KOR signaling in our studies. 
2. We found that spinal MOR and KOR blockade reinstates hyperalgesia, however; we 
cannot exclude pre-synaptic effects of these receptors. Indeed, recent data based on 
conditional MOR KO (MOR flox/Nav 1.8 mice) mice indicates that MORs located on 
central terminals of primary afferent neurons exert inhibitory effects during the remission 
phase of LS (Severino et al., 2018). Similarly, a recent elegant study from the Ross group 
characterized KOR expression and function on primary afferents. They showed that KOR 
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expressed at peripheral and central terminals of peptidergic neurons are involved in the 
control of mechanical postoperative pain (Snyder et al., 2018). Therefore, future studies 
using in situ hybridization, KOR conditional KO (Cai et al., 2016) or chemogenetic 
approaches may clarify the precise population of spinal KOR-expressing neurons 
responsible for the endogenous control of persistent postoperative pain.  
3. We tested only one or two dosages of DOR selective antagonist on figure 3.2 since 
higher doses of these drugs (i.e TIPP(Ψ) 20ug, and Naltrindole10ug) elicited side effects 
such as scratching, biting of back and paws, spontaneous flinching of the paws, tachypnea, 
excessive grooming and jumping that prevented further testing. Moreover, we tested the 
effect of Tipp (Ψ) 10ug i.t. on a separate cohort of 21-day postoperative female mice (data 
not shown) and observed similar effects to the male mice (lack of reinstatement of 
hyperalgesia). Taking into account possible pharmacokinetic differences of the drugs in 
male and female animals, future studies using higher doses of selective DOR antagonists 
in females and DOR KO mice may be beneficial to support the lack of effect of DOR 
activity in LS found in our studies and rule out a possible sex dimorphism in DOR-
mediated LS.  
4. We evaluated sex differences exclusively in stimulus-evoked (mechanical) pain. Spinal 
KOR neurons play a major role in the modulation of thermal pain (Martin et al., 2003; 
Snyder et al., 2018), therefore; dose-response studies and studies evaluating sex differences 
in thermal hypersensitivity (i.e., Hargreaves’ method (Hargreaves et al., 1988) are 
warranted. In addition, the sex differences reported in postoperative pain in clinical studies 
were based on patients’ self-report. Thus, potential sex differences can also be assessed 
using preclinical assessment of ongoing pain (i.e., CPP or CPA) or facial expression as a 
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surrogate for the visual analog scale used in the clinical trials. Furthermore, investigations 
of the effects of KOR antagonists in supraspinal sites involved in pain modulation such as 
the RVM (Ossipov et al., 2014) on 21 day postoperative mice should clarify whether the 
discrete sex differences observed in our studies are due to spinal or supraspinal KOR 
modulation of LS.   
5. As gonadal hormones positively regulate the expression and function of KOR (Harris et 
al., 2004; Chartoff and Mavrikaki, 2015), the outcomes observed in our studies may be 
influenced by the phase of the estrous cycle in female subjects. Therefore, a major 
limitation in our sex difference studies is that we did not assess the effect of gonadal 
hormones in postoperative nociceptive behaviors. Future studies should evaluate the 
behavioral effects of KOR antagonists in different stages of the estrous cycle using vaginal 
smear in regularly cycling females after surgery. Since, pain may affect the regular estrous 
cycle in females, hormone replacement studies may be also be conducted in 
gonadectomized animals. In addition to hormonal studies, the effect of sex chromosomes 
on KOR endogenous analgesia can also be investigated. Sex chromosome genes (XX vs 
XY) in the nociceptive pathways seem to induce changes in nociception and may be 
independent of gonadal hormones (Gioiosa et al., 2008). For example, XX mice present 
higher brain levels of prodynorphin mRNA in the brain compared to XY irrespective of 
sex (Chen et al., 2009). In addition, KOR agonists increase hot plate thresholds in neonatal 
XX mice (Gioiosa et al., 2008). Thus, sex differences in KOR/dynorphin system may also 
be attributable to sex chromosome complements, regardless of hormone levels. 
6. The sex differences in KOR-inhibited LS may also be explained by differences in KOR 
density or dynorphin levels between males and females. We have not measured KOR 
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expression in the dorsal horn of the spinal cord after plantar incision. Recent data from our 
laboratory (experiments performed by Mei Lu) showed that the levels of Oprk1 (KOR 
gene) in the lumbar dorsal horn are significantly higher in naïve and three days after sciatic 
nerve injury (SNI) in female mice. Moreover, KOR gene expression significantly changes 
throughout the course of neuropathic pain development (up to 14 days after SNI) in 
females.  Thus, it is reasonable to speculate that KOR expression can also differ between 
sexes after inflammation. KOR expression levels could be assessed in the ipsilateral vs. 
contralateral L3-L4 dorsal horn at baseline and different timepoints after plantar incision 
and POD-21 in male and female mice using qPCR and in situ hybridization.  
7. In chapter 4, our data showed that KOR activation promotes a very long-lasting 
postoperative analgesia. However, the mechanisms by which KOR signaling is activated 
after surgery and LS stages remain unclear. Levels of dynorphin are reported to be 
increased after surgical incision (Campillo et al., 2010). Interestingly, dynorphin deletion 
does not reverse selective-KOR blockade induced-pain reinstatement after intraplantar 
CFA injection (Walwyn et al., 2016). Thus, one possibility is that injury leads to KOR 
constitutive activation. Recent reports reveal that reinstatement of drug-seeking is 
mediated by KOR constitutive activity in the brain following acute stress (Polter et al., 
2017). However, little is known about the mechanisms that initiate constitutive signaling.  
In vitro and in vivo data indicate that agonist induced-KOR activation leads to the 
phosphorylation of Ser 369 residue at the KOR C-terminus tail (McLaughlin et al., 2004). 
Thus, constitutive activity could be assessed using validated KOR phospho-selective 
antibodies (Lemos et al., 2011) in WT and pro-dynorphin KO mice at different time points 
after surgical incision using IHC or western blots. Alternatively, pharmacological 
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behavioral or radioligand binding studies using i.e., Nor-BNI (KOR inverse-agonist) and 
6--naltrexol as KOR (non-selective) neutral antagonist (Wang et al., 2007; Polter et al., 
2017), can be used to test the GTP-dependent binding capacity and the ability of KOR 
inverse-agonist to reinstate behavioral hyperalgesia in the presence of the neutral 
antagonist.  
8. Our behavioral pharmacological studies indicate that AC1 and downstream cAMP 
pathways drive LS and are inhibited by KOR signaling. Similar to MOR, chronic 
administration of KOR agonists leads to upregulation of AC and cAMP overproduction 
(Avidor-Reiss et al., 1995; Avidor-Reiss et al., 1996; Avidor-Reiss et al., 1997). Therefore, 
as previously demonstrated in the MOR systems (Taylor and Corder, 2014), KOR long-
lasting signaling during postoperative LS may reduce AC1 super activation (cAMP 
overshoot). Thus, the next logical step is to measure cAMP levels after surgical incision. 
First, we could assess levels of cAMP in the lumbar spinal cord to test whether KOR 
antagonist i.t. administration leads to cAMP overshoot in 21-day postoperative mice 
compared to controls. As previously described, cAMP Elisa analyses can be performed in 
lumbar sections of both groups (Corder et al., 2013). 
9. Our results demonstrated that AC1 significantly contributed to LS, which is inhibited in 
part, by KOR signaling. Although, it is conceivable that to a lesser extent, other AC 
isoforms, i.e., the Ca+2-calmodulin-dependent AC, isoform – 8 (AC8) also contributes to 
the induction of LS after surgery, and development of hyperalgesia in females. This 
hypothesis is supported by a recent study in vitro that suggests that NB001 acts primarily 
through attenuation of cAMP accumulation rather than AC1 direct inhibition (Brand et al., 
2013). Also, our pERK experiment showed that KOR blockade markedly reduced, but did 
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not eliminate spinal nociceptive transmission.  Thus, behavioral pharmacological and 
electrophysiological studies using AC8-/-, and/or AC1/AC8 double KO can be used to 
elucidate whether AC8 also participates in the induction and/or maintenance of LS. The 
newly developed AC1-selective inhibitor ST034307 may also be used in future studies 
(Brust et al., 2017). 
10. We did not test in this dissertation whether KOR suppresses a NMDAR (NMDAR 
subtypes) – AC1 pathway. Recent data from our laboratory indicates that NMDAR are 
involved in the maintenance of LS unmasked by the non-selective opioid antagonist NTX. 
Accumulating evidence suggest that AMPA-derived calcium is the predominant post-
synaptic mechanism implicated in post-incisional sensitization (Pogatzki-Zahn et al., 
2017), and possibly also activates Ca2+ - sensitive adenylyl cyclases. Studies recently 
published by our laboratory indicate the contribution of AMPARs to induction and 
maintenance of LS 21 days after intraplantar CFA (Taylor et al., 2019). Therefore, 
multidisciplinary studies including the administration of AMPAR/NMDAR selective 
inhibitors in vivo or ex vivo, calcium imaging and biochemical approaches may help to 
answer whether KOR inhibits an AMPAR and/or NMDA dependent plasticity after 
surgery.  
11. Our behavioral data indicate that persistent postoperative pain is mediated by cAMP-
PKA signaling only in male mice. The lack of effect of PKA activation or inhibition in 
mechanical hypersensitivity in females may reflect the negative regulation of PKA gonadal 
hormones (Dina et al., 2001). We did not control for the female estrous cycle. Thus, it will 
be interesting if future studies evaluate the effect of PKA activation in 21-day postoperative 
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ovariectomized mice and ovariectomized animals receiving estrogen supplementation to 
rule out the influence of estrogen on PKA signaling in our studies.  
12. Our behavioral studies suggest sexual dimorphism in cAMP-dependent pathways 
mediating LS. Thus, biochemical measures of EPAC (i.e., western blots or in situ 
hybridization) and PKA (activity assay and/or western blots) would confirm their 
contribution and sexual dimorphism in LS. Moreover, these studies will help to determine 
the expression and window of activation of these signaling molecules in the dorsal horn 
after injury. As PKA activates several downstream substrates such as ERK1/2 (Kawasaki et 
al., 2004) and CREB (Hoeger-Bement and Sluka, 2003), it is reasonable to speculate that 
i.t. delivery of the PKA activator (6-bnz) in 21-day postoperative mice would show 
significant differences in the expression of these central sensitization markers in the dorsal 
horn of male compared to female mice.  
13. We did not determine the specific Epac isoform involved in LS, in part, due to the lack 
of a selective Epac1 inhibitor. To date, only Epac 2 selective inhibitors (HJC0350) are 
commercially available. Alternatively, the contribution of both Epac isoforms can be 
evaluated using Epac1 and Epac 2 KO mice or siRNA approaches (Cao et al., 2016). 
Furthermore, Epac is upstream of PKC (Hucho et al., 2005; Gu et al., 2016). PKC has a 
central role in the induction and maintenance of spinal nociceptive plasticity (Aley et al., 
2000; Dina et al., 2001). Similar to PKA, PKC also phosphorylates ERK, CREB and 
glutamatergic receptors. Thus, PKC is an interesting next step in the cAMP pathway to be 
investigated in LS. We reason that similar to Epac, PKC activation is required for LS 
maintenance in both sexes. 




APPENDIX 1. Abbreviations 
6Bnz  N6 - Benzoyladenosine- 3', 5'- cyclic monophosphate sodium salt, 
cAMP analog/PKA activator  
8cpt  8-(4-Chlorophenylthio)-2'-O-methyladenosine 3', 5’-cyclic 
monophosphate sodium salt, cAMP analog/EPAC activator  
AC   Adenylyl cyclase 
AC1   Adenylyl cyclase type 1 
AC8   Adenylyl cyclase type 8 
AMPA   alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid 
ANOVA  Analysis of variance 
AUC   Area under the curve 
BL   Baseline, mechanical thresholds 
CaMKII  Ca2+/calmodulin-dependent kinase II 
cAMP   adenosine 3′,5′-cyclic monophosphate 
CB1   Cannabinoid receptor subtype 1 
CB2   Cannabinoid receptor subtype 2 
CFA   Complete Freund’s adjuvant 
CNS   Central nervous system 
CPP   Conditioned place preference 
CREB   cAMP response element binding protein 




DAMGO  [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin, MOR agonist 
DPDPE  ([D-Pen2, D-Pen5] enkephalin), DOR agonist 
DAPI    4', 6-diamidino-2-phenylindole    
DRG    Dorsal root ganglia   
DOR   Delta opioid receptor 
EC50   Half-maximal effective concentration 
EMAX   Maximum possible effect 
Epac   Exchange protein directly activated by cAMP  
ERK   Extracellular-signal-regulated kinases 
GABA   Gamma-aminobutyric acid 
CGRP   Calcitonin gene-related peptide 
GDP   Guanosine diphosphate 
GFAP    Glial fibrillary acidic protein  
GIRK   G-protein linked inward rectifying potassium channel 
GPCR   G-protein coupled receptor 
GRK2   G-protein-coupled receptor kinase 2 
GTP    Guanosine-5'-triphosphate  
IASP   International Association for the Study of Pain  
IB4    Isolectin B4  
Iba-1                Iba-1 ionized calcium-binding adapter molecule -1e  
i.c.v.   Intracerebroventricular 
i.p.   Intraperitoneal 
i.t.    Intrathecal 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KOR   Kappa Opioid Receptor  
LS    Latent sensitization/ Latent pain sensitization  
LTP   Long-term potentiation 
LY   LY2456302, KOR selective antagonist 
MAPK   Mitogen-activated protein kinase 
MOR   Mu opioid receptor 
MORCA  Mu opioid receptor constitutive activity 
MPE   Maximum Possible Effect 
NeuN   Neuronal nuclei 
NK1R   Neurokinin receptor 1 
NMDA  N-methyl-D-aspartate 
Nor-BNI  Norbinaltorphimine dihydrochloride, KOR selective antagonist 
NTX   Naltrexone, opioid receptor non-selective antagonist 
PAG   Periaqueductal gray 
PB   Phosphate buffer 
PBN   Parabrachial nucleus 
PBS   Phosphate buffered saline 
PCR    Polymerase chain reaction  
pERK   Phosphorylated extracellular-signal-regulated kinases 
PIM   Plantar Incision Model 
PKA   Protein kinase A 
PKC   Protein kinase C 
RVM   Rostral ventral medulla 
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SP   Substance P 
TIPPψ   H-Tyr-TicΨ[CH2-NH]Phe-Phe-OH 
vF   von Frey filaments 
VGCC   Voltage gated calcium channel 
VGLUT  Vesicular glutamate transporter   




APPENDIX 2. IASP Taxonomy – Pain nomenclature used in this dissertation 
 
Term Definition 
Allodynia Pain due to a stimulus that does not normally provoke pain. 




Increased responsiveness of nociceptive neurons in the central 
nervous system to their normal or subthreshold afferent input. 
Hyperalgesia Increased pain from a stimulus that normally provokes pain. 
Neuropathic pain Pain caused by a lesion or disease of the somatosensory nervous 
system. 
Neuropathy A disturbance of function or pathological change in a nerve: in one 
nerve, mononeuropathy; in several nerves, mononeuropathy 
multiplex; if diffuse and bilateral, and polyneuropathy. 
Nociception The neural process of encoding noxious stimuli. 
Nociceptive 
neuron 
A central or peripheral neuron of the somatosensory nervous 
system that is capable of encoding noxious stimuli. 
Nociceptive pain Pain that arises from actual or threatened damage to non-neural 
tissue and is due to the activation of nociceptors. 
Nociceptive 
stimulus 
An actually or potentially tissue-damaging event transduced and 
encoded by nociceptors. 
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Nociceptor A high-threshold sensory receptor of the peripheral somatosensory 
nervous system that is capable of transducing and encoding noxious 
stimuli. 
Nociplastic pain Pain that arises from altered nociception despite no clear evidence 
of actual or threatened tissue damage causing the activation of 
peripheral nociceptors or evidence for disease or lesion of the 
somatosensory system causing the pain. 
Noxious stimulus A stimulus that is damaging or threatens damage to normal tissues. 
Pain An unpleasant sensory and emotional experience associated with 




Increased responsiveness and reduced threshold of nociceptive 
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